



06-08-00

Patent  
254/186

Jc828 U.S. PTO  
09/58866



To: BOX PATENT APPLICATION  
Commissioner for Patents  
Washington, D.C. 20231

**NEW APPLICATION TRANSMITTAL - UTILITY**

Sir:

Transmitted herewith for filing is a **Utility** Patent Application:

**Inventor(s):** MARC MOUNIR RAHME

**Title:** THE USE OF AUTONOMIC NERVOUS SYSTEM  
EUROTRANSMITTERS INHIBITION AND ATRIAL  
PARASYMPATHETIC FIBERS ABLATION FOR THE  
TREATMENT OF ATRIAL ARRHYTHMIAS AND TO  
PRESERVE DRUG EFFECTS

**I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):**

63 Page(s) of Written Description  
2 Page(s) Claims  
1 Page(s) Abstract  
\_\_\_\_ Sheets of Drawings ☐ Informal ☐ Formal

**II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:**

- ☒ Declaration  
☒ Power of Attorney ☐ Separate ☒ Combined with Declaration  
☐ Assignment to \_\_\_\_\_ and assignment cover sheet  
☒ Verified Statement establishing "**Small Entity**" under 37 CFR §§ 1.9 and 1.27  
☐ Priority Document No(s):

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EI 088 595 341 US  
Express Mail Label No.

6 June 2000  
Date of Deposit

Valerie Raleigh  
Name of Person Mailing Paper

Valerie Raleigh  
Signature of Person Mailing Paper

- ☐ Information Disclosure Statement w/PTO 1449      ☐ Copy of Citations  
☐ Preliminary Amendment  
☒ Return Postcard

**III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:**

<b>BASIC FILING FEE:</b>						<b>\$690.00</b>
Total Claims	13	-	20	=	0 x \$18.00	\$0.00
Independent Claims	6	-	3	=	3 x \$78.00	\$234.00
Multiple Dependent Claims	\$260	(if applicable)			<input type="checkbox"/>	\$0.00
<b>TOTAL OF ABOVE CALCULATIONS 924</b>						<b>\$924.00</b>
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.						\$462.00
Misc. Filing Fees (Recordation of Assignment -- \$40)						\$0.00
<b>TOTAL FEES DUE HEREWITH</b>						<b>\$462.00</b>

**IV. METHOD OF PAYMENT OF FEES**

- ☒ A check in the amount of \$462.00.  
☐ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of \_\_\_\_\_.  
☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

**V. AUTHORIZATION TO CHARGE FEES**

The Commissioner is authorized to credit any overpayment and to charge any underpayment to Lyon & Lyon's Deposit Account No. **12-2475** for the following:

- ☒ 37 CFR § 1.16 – (Filing fees and excess claims fees)  
☒ 37 CFR § 1.17 – (Any application processing fees)  
☐ 37 CFR § 1.21 – (Assignment recording fees)

**VI. CORRESPONDENCE ADDRESS**

Please send all correspondence to Customer Number 22249:



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
Suite 4700  
633 W. Fifth Street  
Los Angeles, CA 90071

Please direct all inquiries to Charles S. Berkman, at (858) 552-8400.

Respectfully submitted,

LYON & LYON LLP

Dated: 6 June 2000

By: 

Charles S. Berkman  
Reg. No. 38,077

Applicant or Patentee: MARC MOUNIR RAHME  
Serial or Patent No. : TBA  
Filed or Issued: 6 June 2000  
For: THE USE OF AUTONOMIC NERVOUS SYSTEM EUROTRANSMITTERS  
INHIBITION AND ATRIAL PARASYMPATHETIC FIBERS ABLATION FOR THE  
TREATMENT OF ATRIAL ARRHYTHMIAS AND TO PRESERVE DRUG  
EFFECTS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27(b)) – INDEPENDENT INVENTOR**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the above-entitled invention described in

- ☒ the specification filed herewith  
☐ the application serial no. \_\_\_\_\_, filed \_\_\_\_\_.  
☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed or licensed or am under an obligation under contract or law to assign, grant, convey or license any rights in the invention is listed below. **NOTE:** Separate verified statement are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

- ☒ no such person, concern or organization.  
☐ persons, concerns or organizations listed below:

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

MARC MOUNIR RAHME  
Name of Inventor



Signature of Inventor

6 June 2000  
Date

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT**

**THE USE OF AUTONOMIC NERVOUS SYSTEM  
NEUROTRANSMITTERS INHIBITION AND ATRIAL  
PARASYMPATHETIC FIBERS ABLATION FOR THE  
TREATMENT OF ATRIAL ARRHYTHMIAS AND  
TO PRESERVE DRUG EFFECTS**


SD-150894 1

**CERTIFICATE OF MAILING  
(37 C.F.R. §1.10)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL 088 595 341 US  
Express Mail Label No.

6 June 2000  
Date of Deposit

Valerie Raleigh  
Name of Person Mailing Paper  
  
Signature of Person Mailing Paper

## **DESCRIPTION**

THE USE OF AUTONOMIC NERVOUS SYSTEM NEUROTRANSMITTERS  
INHIBITION AND ATRIAL PARASYMPATHETIC FIBERS ABLATION FOR  
THE TREATMENT OF ATRIAL ARRHYTHMIAS AND TO PRESERVE DRUG  
EFFECTS

## **FIELD OF THE INVENTION**

Cardiac rhythm disturbances are a major cause of morbidity and even  
mortality in our ageing population. Most of these rhythms are based on reentry, i.e.  
the continuous circulation of a wavefront of excitation around a functional or  
anatomical circuit such as atrial fibrillation and flutter. Atrial fibrillation could exist as a  
stable state, self-sustained and independent of its initiating trigger in the presence of  
non-uniform distribution (i.e. dispersion) of atrial refractory periods. In addition,  
maintenance of atrial fibrillation may require a critically short wavelength in order to  
sustain reentry. However, the cellular and pathophysiological mechanisms in the  
initiation and maintenance of atrial fibrillation remain poorly understood. It has been  
reported that inducibility and maintenance of this atrial arrhythmia are associated with  
an increased dispersion in atrial refractoriness. In addition, alterations in the  
electrophysiologic properties of the atria affecting wavelength may lead to persistence  
of atrial fibrillation and to the occurrence of reentrant atrial arrhythmias in both in  
vitro and in vivo models. Furthermore, electrical remodeling of the atria may also  
increase the likelihood of the maintenance of this atrial arrhythmia.

Electrophysiological studies suggest that the mechanism of type I atrial flutter  
in humans and in canine models involves a macroreentrant circuit around an  
anatomically or anisotropically defined obstacle with either a partially or fully  
excitable gap. The excitable gap is one of the determinants of the continued circulation  
of the abnormal atrial impulse and in its presence an extrastimulus may excite the  
circuit and reset the tachycardia. Furthermore, the persistent circulation of this  
wavefront is determined by the effective refractory period, the conduction velocity,  
the wavefront and the nature and duration of the excitable gap, i.e. that portion of the  
circuit which has partially or fully recovered its excitability. This excitable gap, in  
part, determined by the size of the reentry circuit and the electrophysiological  
properties of its tissue components.

However, external influences may also significantly modify the susceptibility for the occurrence of atrial arrhythmias via different electrophysiological mechanisms such as the excitable gap characteristics, the effective refractory period duration and dispersion, the conduction velocity, the wavefront duration and propagation forms and the number of the wavelets. Autonomic nervous system tone may implicitly have a role in the pathogenesis of initiation and persistence of supraventricular arrhythmias. In experimental models, both vagal stimulation and acetylcholine application to the heart can nonhomogeneously shorten atrial refractory period and produce either paroxysmal atrial arrhythmia, flutter or fibrillation. In man, the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night which correlates with an immediately preceding increase in vagal drive. Catecholamine administration (Isoproterenol) also shortens the atrial action potential and stimulation of sympathetic nerves shortens atrial refractoriness and increases its dispersion facilitating the induction of atrial fibrillation. In man, attacks of atrial fibrillation have also been reported to be associated with adrenergic activation. Little is known, however, on the possible influence of autonomic nervous system tone on an established stable reentry circuit such as is seen in atrial flutter, an arrhythmia which is frequently difficult to interrupt by pharmacological means, and also on the occurrence of the leading circle phenomena during atrial fibrillation episodes. In a human study of parasympathetic and sympathetic blockade, observations limited to effects on atrial flutter cycle length did not detect any change either in the supine or upright position. No study has yet addressed the effects of autonomic neurotransmitters on the refractory period, duration and composition of the excitable gap and thus, on the viability of an atrial reentry circuit.

Despite considerable advances in our understanding on the mechanism of this atrial arrhythmia, antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems. These drugs are either incompletely effective, may have proarrhythmic properties, and also may increase mortality. Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties, there has been increased interest in class III drugs, which act by increasing action potential duration and refractoriness without blocking sodium channels. The pharmacological control of cardiac arrhythmias using class III antiarrhythmic drugs which prolong the cardiac action potential has

gained interest recently, particularly in view of reports of proarrhythmic and increased mortality associated with the use of class I antiarrhythmic drugs in the treatment of both ventricular and atrial arrhythmias. In addition, there is evidence that drugs with class III antiarrhythmic action may be more effective than the class I antiarrhythmic drugs for conversion and suppression of some cardiac arrhythmias, particularly those due to reentry. This greater efficacy of the class III antiarrhythmic drugs may be due in part to their ability to selectively prolong refractoriness and wavelength and reduce dispersion of refractoriness. Despite extensive investigation in the past, the critical electrophysiologic determinants of antiarrhythmic drug efficacy in specific reentrant tachycardias are not fully delineated. Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms. Both isomers have equal class III activity but only the l-isomer possesses significant  $\beta$ -adrenoceptor blocking activity. d,l-Sotalol, the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current ( $I_{ks}$  and  $I_{kr}$ ) and thus increases the atrial action potential duration and the atrial effective refractory period. At high concentrations, Sotalol can also inhibit the background or inward rectifying  $K^+$  ( $I_{k1}$ ) and decreases the transient outward  $K^+$  current ( $I_{to}$ ). Administration of class III antiarrhythmic drugs has been reported to prevent and/or terminate atrial flutter and fibrillation, an effect correlated with a shortening of the excitable gap and with prolongation of both the atrial arrhythmias cycle length and the refractory period.

The purpose of this invention is to determine the effects of norepinephrine and acetylcholine on the excitable gap composition during a sustained stable atrial flutter, and on the atrial effective refractory period duration and dispersion, atrial conduction velocity and atrial wavelength. Furthermore, this invention illustrates also the influence of autonomic nervous system activation and neurotransmitters infusion on the occurrence of these atrial arrhythmias, and whether these significant effects could alter those of sotalol on the same electrophysiological parameters. This invention also project the possibility for new atrial targets for the use of catheter ablation during the treatment of atrial arrhythmias. These new targets for catheter ablation during an atrial arrhythmia may be the fully excitable tissue, and/or the areas with the greatest density



of parasympathetic innervation such as the tissues near the sinoatrial nodal fat pad and septal.

### **BRIEF SUMMARY OF THE INVENTION**

5           Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced, activated and aggravated by autonomic nervous system tone. Furthermore, the treatment of this atrial arrhythmias are influenced, threaded and degenerated to a proarrhythmic events under the dominant effects of the autonomic nervous system activation. This invention evaluated the significance of sympathetic and  
10           parasympathetic activation by determining the effects of norepinephrine and acetylcholine on the composition of the excitable gap during a stable sustained atrial flutter, on the effective refractory period, on the conduction velocity, and on the wavelength in a canine model of stable atrial flutter. We also evaluated whether norepinephrine and acetylcholine administration can alter class III antiarrhythmic  
15           drug effects in the occurrence of atrial arrhythmias. This invention also evaluated the significance of sympathetic and parasympathetic denervation and activation by determining the direct effects of right and left stellar ganglions (10 Hz, 2 ms) and right vagal (1 Hz, 0.1 ms) stimulation on the atrial effective refractory period duration and dispersion, on the atrial conduction velocity, on the atrial wavelength and on the viability  
20           of the occurrence of atrial fibrillation. This invention also evaluated whether the autonomic nervous stimulation can alter class III antiarrhythmic drug (sotalol) effects in the same electrophysiological parameters described above and on the occurrence of these atrial arrhythmias.

25           In a group of 13 open chest anaesthetised dogs, atrial flutter model was produced during baseline conditions around the tricuspid valve using a Y-shaped lesion in the intercaval area extending to the right atrial appendage. Atrial flutter was induced at the shortest effective refractory period site using fast pacing stimulation (S1S1) of 100-150 ms. This manoeuvre was repeated as much as necessary with more damage in the Y-shaped lesion model to achieve a sustained stable atrial flutter (>10  
30           min) during the baseline conditions. In order to determine the excitable gap duration and composition during this sustained and stable atrial flutter, a diastole was scanned with a single premature extrastimulus, S1S2 (S1S2 = ]refractory period, flutter cycle length[) to define the atrial flutter circuit composition and duration (flutter cycle

length = refractory period + excitable gap). Atrial flutter cycle length, atrial effective refractory period and duration of the excitable gap were then determined. Measures were repeated during a constant infusion into the right coronary artery of norepinephrine (15 µg/min) and acetylcholine (2 µg/min) allowing 15 min for recovery from norepinephrine effects. The effects of norepinephrine and acetylcholine at a constant plasma level of d-sotalol or d,l-sotalol (0.8 mg/kg + 0.4 mg/kg/hr) were also studied in 2 different groups of chloralose anaesthetised dogs on the same electrophysiological parameters described above.

In a group of 14 anaesthetised open chest dogs, atrial fibrillation was induced by fast pacing and up to 10 attempts of arrhythmia initiations during baseline condition, vagal denervation, right and left vagal stimulation #1 (1 Hz, 0.1 ms), right and left stellar ganglions denervation, right and left vagal stimulation #2 (1 Hz, 0.1 ms), right and left stellar ganglions stimulation (10 Hz, 2 ms), and right and left vagal stimulation (1 Hz, 0.1 ms) associated with right and left stellar ganglions stimulation (10 Hz, 2 ms). Under the same conditions described above, the effective refractory period duration and dispersion (at S1S1 = 200 ms), the conduction velocity and the wavelength are determined. Atrial fibrillation occurrence was evaluated by the mean duration of 10 atrial fibrillation episodes at baseline (for a group of animals when none of the 10 atrial fibrillation episodes at baseline were lasting more than 3 minutes) and following each of the conditions described above.

In summary, both neurotransmitters infusions (acetylcholine >> norepinephrine) significantly increased the occurrence of the initiation of atrial flutter and decreased the duration of its maintenance by rapid (less than 2 minutes) conversion to a non sustained atrial fibrillation and then to a sinus rhythm state. Both neurotransmitters significantly increased the safety margin of excitability ahead of the wavefront and decreased the effective refractory. Autonomic and, in particular, vagal effects significantly diminish the action of pure class III antiarrhythmic drug, d-sotalol. However, in the presence of d,l-sotalol, a class III combined with anti-adrenergic effects, only acetylcholine still completely reversed its electrophysiological effects. This suggests that class III antiarrhythmic drugs with class II properties could resist the effects of sympathetic but not that of vagal activation. The effects of autonomic nervous system stimulation also significantly increased the occurrence of atrial fibrillation initiation and persistence. The effects of vagus activation significantly exceed those of sympathetic on the

occurrence of atrial fibrillation, on the atrial effective refractory period duration and dispersion, on the conduction velocity and on the wavelength. In a particular interest, when the stellar ganglions denervation facilitates the occurrence of the initiation of a non sustained atrial fibrillation following the premature stimulation (S1S2) (data described the relation between initiation vs. duration of atrial fibrillation are not presented in this invention), the vagal denervation significantly reduced its initiation and maintenance. Furthermore, in the presence of class III drug therapy, the vagal stimulation significantly and markedly reversed the antiarrhythmic therapeutic effects of d,l-sotalol. These results demonstrate an absolute and emergent need to consider the effects of the presence and of the activation of parasympathetic nervous system tone during the pharmacological treatment of atrial arrhythmias. In addition, this invention targets the areas with the greatest density of parasympathetic innervation for ablation, such as the areas located near the sinoatrial nodal fat pad and septal, for the treatment of atrial arrhythmias during a catheter ablation manner.

### **DETAILED DESCRIPTION OF THE INVENTION**

The main purpose of this invention was to study the significant effects of autonomic nervous system on the atrial electrophysiologic parameters related to the pre-conditioning, initiation, persistence and termination of atrial fibrillation and flutter. Furthermore, this invention evaluated whether the significant effects of autonomic nervous system on the atrial electrophysiological parameters and on the occurrence of atrial arrhythmias could change those of class III antiarrhythmic drugs.

#### **Autonomic Nervous System Effects on Atrial Tissue:**

The effects of sympathetic neural activity on the heart are gradually developed and receded, whereas the inhibitory effects of vagal activity appear and disappear rapidly. The automatic cells in the heart respond promptly to vagal stimulation within a steady-state value of two cardiac cycles. The ability of the vagus nerves to regulate heart rate beat by beat could be explained by the speed at which the neural signal is rapidly transduced to a cardiac response and by also by the rapidity of the processes that restore the basal heart rate when vagal activity ceases. The mechanisms of this rapid development of vagal effects on heart rate will be related to: 1) the acetylcholine regulated potassium channels; 2) the hyperpolarization activated channels, which

conduct the If current; and 3) the calcium channels. The acetylcholine and the If channels could both respond rapidly to vagal activity. The If and Ica channels are directly involved in generating the slow diastolic depolarisation in sinus node cells. The release of acetylcholine interacts with cardiac muscarinic receptors that are coupled to its regulated potassium channels directly through G proteins without an interaction of a slow second messenger system. These potassium channels are fully activated by this release of acetylcholine within a few milliseconds. The relatively slow development of the sympathetic responses has been attributed mainly to the inclusion of a second messenger system, notably the adenylyl cyclase system, in the cascade of events that transduce the neuronal release of norepinephrine into a change in cardiac performance. The chronotropic response of the heart to sympathetic activation is mediated mainly via several types of ion channels, such as Ica and If currents. This second messenger system is too slow to permit beat-by-beat regulation of cardiac function. The norepinephrine released from the sympathetic nerve endings is removed from the cardiac tissues much more slowly than is the acetylcholine that is released from the vagal terminals. Then, the atrial tissue and the related ionic currents (Ica, If) are submitted to the sympathetic neural activity after a certain delay of ganglion stellar stimulation. Furthermore, during the study of vagal-sympathetic interaction, the on-set effects of sympathetic stimulation are considered in the presence of existing vagal stimulation effects on atrial tissue and not in the on-set of this vagal stimulation effects.

#### **Autonomic Nervous System Effects in Atrial Arrhythmias:**

Recently, it has become increasingly recognised that beyond an understanding of the electrophysiological behaviour of an isolated reentry circuit, it is necessary also to be aware of possible external influences on the atrial arrhythmias occurrence and on the related atrial electrophysiological parameters such as the effective refractory period duration and dispersion, the conduction velocity, the wavelength and the excitable tissue during these atrial arrhythmias. Variations of autonomic tone have been hypothesised to have a role in the pathogenesis of supraventricular arrhythmia. For example, it has long been known that vagal stimulation or acetylcholine application to the heart can produce either atrial flutter or fibrillation, and can nonuniformly shorten atrial refractoriness periods, thus increasing the regional

differences in atrial refractory period. In man, the onset of atrial fibrillation has a diurnal distribution with a statistically significant peak occurring at night. Further, spectral analysis of heart rate variability has suggested an increase in vagal drive immediately preceding the onset of atrial arrhythmia. Sympathetic stimulation or administration of catecholamines can also influence atrial electrophysiological properties. Isoproterenol shortens the atrial action potential and stimulation of sympathetic nerves shortens slightly atrial refractory period and can facilitate induction of atrial fibrillation. Furthermore, in man, attacks of atrial fibrillation have been reported to be associated with adrenergic activation. Stimulation of the right stellar ganglions produces localised shortening of the refractory period, increases the dispersion of refractoriness and increases the vulnerability to re-entrant arrhythmias.

The majority of the above observations have, however, been made with respect to atrial fibrillation and not atrial flutter. Indeed, very little is known of the influence of the autonomic nervous system tone on the electrophysiological characteristics of tissue within the circuit. In the only human study of autonomic system effects on atrial flutter, parasympathetic and sympathetic blockade with intravenous atropine and propranolol did not change atrial flutter cycle length either in the supine or upright position. Many of these patients were however on Class IA antiarrhythmics which in themselves have an anticholinergic effect. Furthermore, observations limited to cycle length although useful, do not describe the complex effects of the autonomic nervous system on the electrophysiological properties of tissue participating in the circuit. Only a study of the duration of the excitable gap can elucidate how the viability of the flutter circuit is modulated by autonomic effects. Indeed, properties such as atrial refractoriness and conduction velocity are influenced by autonomic input can be determined to measure the influence of autonomic nervous system on atrial arrhythmias.

Either adrenergic or vagal stimulation can favor the onset of atrial fibrillation through complex mechanisms of shortening of the atrial refractory period, affecting the heterogeneity of refractoriness, the conduction time and the resultant wavelength of the propagate of this atrial arrhythmias. Atrial fibrillation starts with a period of rapid ectopic activity that may be caused by discharge of an autonomic focus, or afterpotentials, particularly in the setting of an enhanced catecholamine state. Vagal tone stimulation initiates atrial fibrillation by hyperpolarization in the atrial tissues

and fibres, an effect that does not favor either delayed afterdepolarization or pacemaker activity. Thus, it may facilitate the conditions for the reentry initiation because the duration of the P waves may actually become shorter than the time required to excite the whole atria. However, for those factors may also be the conditions for the perpetuation or the termination of those re-entrant atrial arrhythmias. Clinical paroxysmal atrial arrhythmias suggesting a predominant vagal mechanism often display a pattern of atrial fibrillation with alternates of atrial flutter. In contrast, atrial fibrillation dependent of adrenergic activity is most likely related to ectopic automatic foci explained by their ECG appearance. The onset of atrial fibrillation that occurs in the setting of rest or digestive periods, and is preceded by a progressive heart rate decrease, could be related to a vagal activation mechanism. However, palpitations starting at exercise or stress are related to adrenergic mediation.

### **Class III Antiarrhythmic Drugs Mechanisms in Atrial Arrhythmias:**

Electrophysiological studies suggest that the mechanism of type I atrial flutter in humans and in canine models involves a macroreentrant circuit around an anatomically or anisotropically defined obstacle with either a partially or fully excitable gap. The excitable gap is one of the principle determinant of the continued circulation of the abnormal atrial impulse and in its presence an extrastimulus can preexcite the circuit and reset the tachycardia. Atrial fibrillation, a reentrant arrhythmia, is more likely to occur in the presence of an abnormally shortened atrial effective refractory period and increased dispersion of the effective refractory period. In addition, abnormally depressed conduction velocity and anatomic obstacles may play a role in the reentrant mechanism of atrial fibrillation. Experimental studies have suggested that prolongation of atrial wavelength and a reduction in effective refractory dispersion may be critical determinants of the efficacy of antiarrhythmic drugs in terminating and suppressing reentrant atrial arrhythmias. Both of these salutary electrophysiological effects are produced by class III antiarrhythmic drugs, such as sotalol. Despite their favourable electrophysiological profile, however, the class III drugs are not more effective than the class I drugs in suppressing atrial fibrillation in humans, with only 50% to 65% of patients in sinus rhythm after 6 months of therapy. In addition, the organ toxicity and potential life-threatening ventricular proarrhythmia associated with antiarrhythmic drugs further limit their use

for treating atrial fibrillation. Because of the limited efficacy and potential adverse effects of antiarrhythmic drugs that modulate cardiac ion channels, new approaches to antiarrhythmic drug therapy must be developed. One possible approach is the modulation of membrane receptors that play a role in controlling normal cellular electrophysiology. Despite considerable advances in our understanding on the mechanism of this atrial arrhythmia, antiarrhythmic drug therapy to produce and maintain sinus rhythm is fraught with a variety of problems. These drugs are either incompletely effective, may have proarrhythmic properties, and also may increase mortality. Since some of the more dangerous proarrhythmic potential of antiarrhythmic drugs appears to be related to sodium channel blocking properties, there has been increased interest in class III drugs, which act by increasing action potential duration and refractoriness without blocking sodium channels. Sotalol is one such class III antiarrhythmic drugs which can exist in either the d- or l-isomer forms. Both isomers have equal class III activity but only the l-isomer possesses significant  $\beta$ -adrenoceptor blocking activity. d,l-Sotalol, the racemic, therefore has both class II and class III properties. It has been used both to terminate atrial arrhythmias and to prevent their recurrence following cardioversion. It blocks both the slow and rapid component of the delayed rectifier potassium current ( $I_{ks}$  and  $I_{kr}$ ) and thus increases the atrial action potential duration and the atrial effective refractory period. At high concentrations sotalol can also inhibit the background or inward rectifying  $K^+$  ( $I_{kl}$ ) and decreases the transient outward  $K^+$  current ( $I_{to}$ ). Administration of class III antiarrhythmic drugs has been reported to prevent and/or terminate atrial flutter an effect correlated with a shortening of the excitable gap and with prolongation of both the atrial flutter cycle length and the refractory period.

In a recent study in common human atrial flutter, edrophonium which blocks acetylcholinesterase activity had no significant effect on monophasic atrial action potential duration or atrial flutter cycle length. However, this study had some limitations. For example, the atrial monophasic action potentials were not obtained directly from the atrial flutter circuit. Furthermore, cholinesterase inhibition would not necessarily produce any change in action potential duration in the absence of simultaneous vagal activity. This invention also presents some limitations in the part of neurotransmitters infusion during the sustained atrial flutter: First, neurotransmitter infusion does not necessarily reproduce the synaptic cleft concentrations which occur

with autonomic nervous system stimulation. Second, autonomic fibers may be non homogeneously distributed in the atrium and this distribution is different for the vagal and sympathetic systems. The latency time and duration of the physiological response are also different. This may contribute to a discrepancy between the effects of neurotransmitter infusion, which may produce a more homogeneous effect compared to the non homogeneous autonomic fiber stimulation. Finally, at the level of the neuroeffector junction and beyond, the effects of neurotransmitter infusion may differ from the effects of autonomic fiber stimulation. Parasympathetic and sympathetic system stimulation interact in four ways: (1) vagal stimulation inhibits the release of norepinephrine at sympathetic nerve terminals; (2) sympathetic stimulation releases neuropeptide Y, which in turn interferes with the actions of vagal stimulation, possibly by inhibiting the release of acetylcholine; (3)  $\alpha$ -adrenergic stimulation with phenylephrine attenuates the bradycardia induced by direct vagus nerve stimulation; and (4) acetylcholine antagonizes the intracellular production of cyclic AMP by catecholamines. Therefore, the effects we observe with infusion of acetylcholine and norepinephrine likely do not reproduce quantitatively the effects of autonomic nerve activity. Nevertheless, these qualitative effects demonstrate an important modulation of atrial flutter excitable gap which can be clinically significant.

#### Methods:

Atrial Flutter protocol: All experiments described were in accordance with institutional guidelines for animal experimentation. Fourteen mongrel dogs of either sex, weight 29-45 kg, were studied in the post-absorptive state. General anaesthesia was induced with sodium thiopental (25 mg/kg iv.) and maintained with chloralose (80 mg/kg iv. bolus supplemented by 20 mg/kg/hr maximum as needed). The dogs were intubated and ventilated (Harvard pump) with room air (10 breaths/min, tidal volume to achieve a maximum inspiratory pressure of 20 cm water) to maintain arterial pH 7.35-7.45 and  $\text{PaO}_2 > 80$  mm Hg. Arterial and venous cannulae were inserted in the left femoral artery and vein by direct cut down for blood pressure monitoring and drug administration, respectively. An additional venous cannulae was inserted in the right femoral vein or in the right internal jugular vein for blood sampling. Muscular relaxation was then induced with gallamine triethiodide (Flaxedil 100) 3 mg/kg intravenously. A right thoracotomy was performed via the fourth or



fifth intercostal space and the pericardium was incised to provide access to the vena cava and the right atrium. According to the procedure described by Frame et al., (1986) the tissue on a line extending from the superior to the inferior venae cavae was clamped, incised and sewn over. A second line, extending from the first two-thirds of the way toward the tip of the right atrial appendage and parallel to 1-2 cm above the atrioventricular groove, was similarly incised and sewn over. Five close (2-4 mm) bipolar epicardial silver electrodes (insulated except at the tip) for stimulating and/or recording were sewn around the base of the right atrium within 1 cm of the tricuspid annulus. Three were positioned on the anterior surface and two on the posterior surface (Derakhchan K, et al., 1994). An arterial cannula was inserted in the right coronary artery for neurotransmitter infusion.

Measurement of electrophysiologic parameters: A single lead (II) surface electrocardiogram, atrial electrograms from each of the 5 bipolar electrodes, and the femoral arterial pressure were monitored and recorded using a Nihon Kohden polygraph (Model RM6008). Data were also stored on a Hewlett-Packard tape recorder. Atrial flutter was induced by burst stimulation (20-30 beats at basic cycle length < 100 ms). During stable flutter (cycle length variation < 10 ms), a premature stimulus was introduced at the site located on this re-entry circuit after every 20th spontaneous beat (T) in 2 ms decrements beginning at coupling intervals equal to the cycle length of this atrial tachycardia. The interval between the last spontaneous beat and the response to the subsequent premature stimulus (Coupling Interval) as well as the interval between the response to the premature stimulus and the subscript ( $T_1$ ) tachycardia beat (Return Cycle) were measured (peak-to-peak) at the electrode distal to the stimulating site (in the direction of wavefront propagation). Measurements were made at a paper speed of 100 mm/s using a Digimatic Caliper (Mitutoyo Corporation, Tokyo) which has a resolution of 0.01 mm. Graphs describing the relationship between the Return Cycle (ordinate) and the Coupling Interval (abscissa) of the premature beat or reset-response curves were constructed using points where  $(T - T_1) < 2(T - T)$  by more than 3 ms. The refractoriness duration of this re-entry circuit was defined as the shortest coupling interval which reset this tachycardia. This excitable gap is calculated from the tissue which conducted the premature beat. The excitable gap tissue was thus the interval between the refractoriness and the total cycle length of this atrial arrhythmia. A line was fitted to the ascending portion of the reset-response

curve, using all points where the Return Cycle > flutter cycle length. The duration of the flat portion was then taken from the intersection of this line with a horizontal line drawn at the flutter cycle length on the ordinate. The excitable gap was characterized by the reset-response technique as previously described by Derakhchan et al. (1994).  
5 It assumes that the reentry circuit is located in the muscle ring immediately above the tricuspid valve as has been previously demonstrated (Frame et al., 1986) and that its location in the presence of drug is unchanged. Measures were performed under control conditions before and then during a constant infusion of norepinephrine into the right coronary artery (15 µg/min) and again during an acetylcholine infusion (2 µg/min) into  
10 the same artery after allowing 15 minutes for recovery from norepinephrine effects. Completion of the entire protocol on drug usually required one hour.

Statistical analysis: Data are presented as mean ± standard deviation of the mean. When multiple measurements were performed in the same population, statistical comparisons were done using one way repeated-measures ANOVA with  
15 Bonferroni's correction for pairwise multiple comparisons. For all tests, a value of  $P < 0.05$  was considered to be statistically significant (details of statistics of each parameter are presented with the in the section: Description of Tables). Linear regression as described in Methods was determined to characterise the increasing portion of the reset-response curve.

Atrial Fibrillation protocol: Fourteen mongrel dogs weighing 19-30 kg were anaesthetised with morphine (2 mg/kg i.m.) and  $\alpha$ -chloralose (100 mg/kg iv.) and ventilated by a respirator (NSH 34RH, Harvard Apparatus, South Natick, Mass.) via an endotracheal tube at a rate of 20-25 breaths per minute with a tidal volume  
20 obtained from a nomogram. Arterial blood gases were measured to ensure adequate oxygenation ( $\text{SaO}_2 > 90\%$ ) and physiological pH (7.38-7.45). Body temperature was maintained with a homiothermic heating blanket. Catheters were inserted into the left femoral artery and both femoral veins and kept patent with heparinized saline solution (0.9%). A median sternotomy was performed, an incision was made into the  
25 pericardium extending from the cranial reflection to the ventricular apex, and a pericardial cradle was created. A pair of Teflon-coated stainless steel bipolar hook electrodes, one for stimulation and the other for recording atrial electrograms, were inserted intramural into the tip of the right atrial appendage. The position of the  
30 stimulating electrodes were located in the right atrial appendage (RA-1), left atrial

appendage (LA-2), inferior vena cava (IVC-3), medial vena cava (MVC-4) and superior vena cava (SVC-5). A programmable stimulator and a stimulus isolator (Bloom Assoc., Flying Hills, Pa.) were used to deliver 4-msec square-wave pulses. Operational amplifiers (Bloom Association) and a Mingograp T-16, 16 channel recorder (Siemens-Elema Ltd., Toronto, Canada) were used to record the six standard surface electrocardiogram leads, arterial pressure, and stimulus artifacts. Electrocardiographic recordings were obtained at a paper speed of 200 mm/sec.

Activation Mapping: Five thin plastic sheets containing 112 bipolar electrodes with 1 mm interpolar and 6 mm interelectrode distances were sewn into position on atrial epicardial surface. One sheet was placed under the root of aorta to cover the anterior aspect of the atrial appendages and Bachman's bundle. Three sheets were sewn to the posterior aspects of the atrial appendages and to the free walls. The parietal pericardium was gently separated, and a fifth plaque was placed between the pulmonary arteries and veins. Each signal was filtered (30 to 400 Hz), digitized with 12-bit resolution and 1-KHz sampling rate, and transmitted into a microcomputer (model 286, Compaq Computer, Houston, Tex.). Software routines were used to amplify, display, and analyse each electrogram signal as well as to generate activation maps. Each electrogram was analyzed with computer-determined peak-amplitude criteria and was reviewed manually. The accuracy of activation time measurements was  $\pm .5$  ms. The data were downloaded on high-density diskettes for subsequent off-line analysis. Isochrone maps and activation times for each activation were recorded by the use of IBM ink jet printer. Hardware and software for the mapping system were obtained from Biomedical Instrumentation, Inc., Markham, Ontario.

Autonomic Nervous System model: Both cervical vagal trunks were isolated and decentralised approximately 3 cm proximal to the bifurcation of the common carotid artery, and bipolar hook electrodes (stainless steel insulated with Teflon except for the terminal 1-2 cm) were inserted via a 21-gauge needle into the middle of each nerve, with the electrode running within and parallel to vagal fibers for several centimetres. Both right and left stellar ganglions were found between the 2-3 intercostal level, and isolated and decentralised, then a bipolar hook electrodes were inserted via a 21-gauge needle into the dorsal and ventral ansae of each stellar ganglion. The left and right stellar ansae were stimulated with square-wave pulses of 2 ms duration, 10 Hz frequency and 6 volts. Adequate stellar stimulation was verified by an increase in arterial

systolic/diastolic pressure (from the left side) and in heart rate (from the right side).

Bilateral vagal nerve stimulation was delivered by an SD-9F stimulator (Grass Instruments, Inc., Quincy, Mass.), with a pulse width of 0.1 msec and a frequency of 1 Hz, with an amplitude of stimulation of 3-10 V, adjusted in each dog to two thirds of the threshold for the production of asystole under control conditions. At a constant basic cycle length of 200 ms, we have determined the effective refractory period duration and the conduction velocity at baseline, vagal and sympathetic denervation. Fifteen seconds after the initiation of vagal (1Hz, 0.1ms) and sympathetic stimulation (10Hz, 2ms), we started to determine the effective refractory period and conduction velocity duration. Atrial fibrillation initiations were determined by short burst (1-3 seconds) of atrial pacing at a cycle length of 60-100 ms and with a current amplitude of four times the diastolic threshold for atrial capture. Atrial fibrillation duration was determined by the mean of 10 atrial fibrillation episodes during baseline conditions, vagal denervation, vagal stimulation (1Hz, 0.1ms) during 3 minutes, sympathetic denervation, vagal stimulation (1Hz, 0.1ms) during 3 minutes, and on the combined vagal (1Hz, 0.1ms) and sympathetic (10Hz, 2ms) stimulation during 3 minutes. If the duration of any atrial fibrillation episode on vagal or sympathetic stimulation was > 3 minutes, no further stimulation are required. Animals with atrial fibrillation duration episodes > 3 minutes at baseline conditions are excluded from this study.

### Results:

Reversal of d-sotalol effects on the atrial flutter circuit compositions by autonomic nervous system neurotransmitters:

The characteristics of the atrial flutter circuit are detailed in Table 1 from 6 animals. Both norepinephrine and acetylcholine infusion significantly shortened the effective refractory period duration. However, only acetylcholine infusion significantly shortened the atrial flutter cycle length and the excitable gap duration. In the presence of pure class 3 antiarrhythmic drug, d-sotalol, both norepinephrine and acetylcholine significantly reversed the effects of d-sotalol on the atrial flutter cycle length and on the effective refractory period duration, but only acetylcholine infusion significantly reversed d-sotalol effects on the excitable gap duration.

Selective reversal of d,l-sotalol effects on the atrial flutter circuit compositions by the parasympathetic nervous system neurotransmitters:

The characteristics of the atrial flutter circuit are detailed in Table 2 from 7 animals. Acetylcholine infusion significantly decreased the effective refractory period duration and increased the excitable gap duration. In the presence of d,l-sotalol, a class 3 combined with anti-adrenergic effects, acetylcholine significantly reversed d,l-sotalol effects on the atrial flutter cycle length, on the effective refractory period and on the excitable gap duration.

Effects of autonomic nervous system on the atrial refractory period duration and dispersion, on the atrial conduction velocity and wavelength, and on the occurrence of atrial fibrillation after its initiation:

The results on the atrial fibrillation are detailed in Table 3 from 14 animals. Vagal denervation effects compared to the baseline conditions, significantly decreased the atrial fibrillation duration, the effective refractory period dispersion and the conduction velocity, and significantly increased the effective refractory period duration. Sympathetic denervation did not significantly changed the effects produced by the vagal denervation. However, sympathetic stimulation significantly reversed the effects of autonomic denervation on the atrial effective refractory period duration. In contrast, vagal stimulation before and after sympathetic denervation significantly reversed the effects of autonomic denervation on the atrial fibrillation duration, on the effective refractory period duration and dispersion and on the conduction velocity. Vagal stimulation effects compared from baseline conditions, significantly increased the atrial fibrillation duration and the conduction velocity, and significantly decreased the effective refractory period duration. The combined effects of sympathetic-parasympathetic stimulation compared to those of parasympathetic stimulation alone were significantly different only on the conduction velocity, however, these combined effects compared to those of sympathetic stimulation alone are significantly different on the effective refractory period duration and dispersion and on the conduction velocity.

#### **DESCRIPTION OF TABLES AND STATISTICS:**

**TABLE 1.**     **Reversal of d-sotalol effects on the atrial flutter circuit compositions by autonomic nervous system neurotransmitters: Statistical**

analysis for atrial flutter cycle length (AFICL), effective refractory period duration (ERP<sub>dur</sub>) and excitable gap duration (EG<sub>dur</sub>) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. Data for d-sotalol are not shown in this invention.

	<u>Baseline</u>	<u>NE</u>	<u>ACh</u>	<u>d-S+NE</u>	<u>d-S+ACh</u>
AFICL	132±14	133 ± 12	123 ± 15 <sup>*†</sup>	131 ± 8 <sup>†</sup>	122 ± 9 <sup>*†</sup>
ERP <sub>dur</sub>	105 ± 9	86 ± 9 <sup>*†</sup>	65 ± 5 <sup>*†</sup>	98 ± 8 <sup>†</sup>	78 ± 8 <sup>*†</sup>
EG <sub>dur</sub>	26 ± 10	44 ± 4 <sup>†</sup>	48 ± 16 <sup>*†</sup>	30 ± 13	44 ± 12 <sup>†</sup>

Values are expressed as Mean ± SD (ms) from 6 animals.

\*P < 0.05, significant difference from Baseline

<sup>†</sup>P < 0.05, significant difference from d-sotalol

**Abbreviations:**      **ACh:** Acetylcholine, **AFICL:** Atrial Flutter Cycle Length, **d-S:** d-Sotalol, **EG<sub>dur</sub>:** Excitable Gap duration, **ERP<sub>dur</sub>:** Effective Refractory Period duration, **NE:** Norepinephrine.

**TABLE 2. Selective reversal of d,l-sotalol effects on the atrial flutter circuit compositions by parasympathetic neurotransmitters:** Statistical analysis for atrial flutter cycle length (AF<sub>ICL</sub>), effective refractory period duration (ERP<sub>dur</sub>) and excitable gap duration (EG<sub>dur</sub>) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. Data for d,l-sotalol are not shown in this invention.

	<u>Baseline</u>	<u>NE</u>	<u>ACh</u>	<u>d,1-S+NE</u>	<u>d,1-S+ACh</u>
AF <sub>ICL</sub>	133 ± 15	132 ± 8 <sup>†</sup>	119 ± 17 <sup>†</sup>	144 ± 11 <sup>*</sup>	126 ± 7 <sup>†</sup>
AERP	105 ± 15	93 ± 7 <sup>†</sup>	64 ± 4 <sup>*†</sup>	121 ± 13 <sup>*</sup>	84 ± 14 <sup>*†</sup>
EG	27 ± 4	39 ± 3	50 ± 16 <sup>*†</sup>	22 ± 12	42 ± 13 <sup>*†</sup>

Values expressed as Mean ± SD (ms) from 7 animals.

\*P <0.05, significant difference from baseline

<sup>†</sup>P <0.05, significant difference from d,l-sotalol

**Abbreviations:** ACh: Acetylcholine, AF<sub>ICL</sub>: Atrial Flutter Cycle Length, d,l-S: d,l-Sotalol, EG<sub>dur</sub>: Excitable Gap duration, ERP<sub>dur</sub>: Effective Refractory Period duration, NE: Norepinephrine.

**TABLE 3. Effects of autonomic nervous system on atrial effective refractory period duration and dispersion, atrial conduction velocity and wavelength, and on the duration of atrial fibrillation:** Statistical analysis for atrial fibrillation duration (AF<sub>dur</sub>), effective refractory period duration (ERP<sub>dur</sub>), effective refractory period dispersion (ERP<sub>disp</sub>), conduction velocity (CV) and wavelength (WL) are performed using one way repeated measures analysis of variance with Bonferroni's corrected method as shown in the following section for each parameter. As shown in the following statistics for each parameter, the number of animals used with each intervention are different according to the ability to realise the correct measurements.

	Bas	V-D	V1-S1	(V+S)-D	S-S10	V2-S1	(V-S1)+(S-S10)
<b>AF<sub>dur</sub></b>	34 ± 31	16 ± 19*	208 ± 21* <sup>†</sup>	8 ± 10* <sup>†α</sup>	-	209 ± 29* <sup>†β</sup>	201 ± 22* <sup>†β</sup>
<b>ERP<sub>dur</sub></b>	99 ± 14	110 ± 13*	89 ± 15* <sup>†</sup>	113 ± 13* <sup>α</sup>	102 ± 11* <sup>†αβ</sup>	90 ± 15* <sup>†βφ</sup>	87 ± 12* <sup>†βφ</sup>
<b>ERP<sub>disp</sub></b>	16 ± 3	11 ± 3*	19 ± 3 <sup>†</sup>	13 ± 4* <sup>α</sup>	13 ± 4 <sup>α</sup>	17 ± 4* <sup>†βφ</sup>	17 ± 6* <sup>†βφ</sup>
<b>CV</b>	100 ± 16	90 ± 12*	108 ± 15* <sup>†</sup>	89 ± 10* <sup>α</sup>	95 ± 14 <sup>α</sup>	111 ± 16* <sup>†βφ</sup>	115 ± 15* <sup>†αβφ</sup>
<b>WL</b>	10 ± 2	10 ± 1	9 ± 2	10 ± 2	10 ± 2	10 ± 2	10 ± 2

Values are expressed as Mean ± SD from 14 animals. (n=13 for ERP<sub>dur</sub> and ERP<sub>disp</sub> on (V<sub>2</sub>-S1)+(S-S10) conditions; n = 12 for CV and WL; n=7 for AF<sub>dur</sub>). ERP<sub>dur</sub> and ERP<sub>disp</sub> are expressed in ms, CV in cm/s, WL in cm, AF<sub>dur</sub> in s. ERP<sub>dur</sub>, ERP<sub>disp</sub> and CV are determined at a basic cycle length (S1S1) of 200 ms, AF<sub>dur</sub> are determined from the mean duration of 10 AF after its initiations.

\*P < 0.05, significant difference from baseline, <sup>†</sup> P < 0.05, significant difference vs. V-D, <sup>α</sup> P < 0.05, significant difference vs. V<sub>1</sub>-S1, <sup>β</sup> P < 0.05, significant difference vs. (V+S)-D, <sup>φ</sup> P < 0.05, significant difference vs. S-S10.

**Abbreviations:** **AF<sub>dur</sub>**: Atrial Fibrillation duration, **Bas**: Baseline conditions, **CV**: Conduction Velocity, **ERP<sub>dur</sub>**: Effective Refractory Period duration, **ERP<sub>disp</sub>**: Effective Refractory Period dispersion, **V-D**: Vagal Denervation, **V<sub>1</sub>-S1**: Vagal Stimulation at 1 Hz before sympathetic denervation, **(V+S)-D**: Autonomic Nervous System (Vagal and Sympathetic) Denervation, **S-S10**: Sympathetic Stimulation at 10 Hz, **V<sub>2</sub>-S1**: Vagal Stimulation at 1 Hz after right and left stellar ganglions denervation, **(V-S1)+(S-S10)**: Vagal Stimulation at 1 Hz combined with Sympathetic Stimulation at 10 Hz, **WL**: Wavelength.



## Reversal of d-sotalol effects on the AF1CL by NE and ACh

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d-s	-6- d-S+NE	-7- d-S+ACh
1	1.0000	106.0000	118.0000	96.0000	data	122.0000	110.0000
2	2.0000	131.0000	124.0000	120.0000	data	126.0000	120.0000
3	3.0000	140.0000	144.0000	130.0000	data	128.0000	126.0000
4	4.0000	134.0000	130.0000	128.0000	data	130.0000	122.0000
5	5.0000	136.0000	132.0000	122.0000	data	134.0000	118.0000
6	7.0000	146.0000	150.0000	140.0000	data	144.0000	136.0000
7							
8							
9Mean		132.1667	133.0000	122.6667	data	130.6667	122.0000
10SD		13.8335	12.0499	14.8414	data	7.6594	8.6718
11SEM		5.6475	4.9193	6.0590	data	3.1269	3.5402

10

15

20

25

30

**Reversal of d-sotalol effects on the AFICL by NE and ACh**

## One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.0706)

Equal Variance Test: Passed (P = 0.6738)

Group	N	Missing
Baseline	6	0
NE	6	0
ACh	6	0
d-S	6	0
d-S+NE	6	0
d-S+ACh	6	0

Group	Mean	Std Dev	SEM
Baseline	132.2	13.83	5.65
NE	133.0	12.05	4.92
ACh	122.7	14.84	6.06
d-S	data	12.32	5.03
d-S+NE	130.7	7.66	3.13
d-S+ACh	122.0	8.67	3.54

Power of performed test with alpha = 0.0500: 1.0000

Source of Variance	DF	SS	MS
Between Subjects	5	3678.0	735.6
Between Treatments	5	1452.0	290.4
Residual	25	535.0	21.4
Total	35	5665.0	

Source of Variance	F	P
Between Subjects		
Between Treatments	13.6	0.00000188
Residual		
Total		

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.00000188). To isolate the group or groups that differ from the others use a multiple comparison procedure.

## All Pairwise Multiple Comparison Procedures (Bonferroni's method):

Comparison	Diff of Means	t	P<0.05
Baseline vs d-S+ACh	10.167	3.807	Yes
Baseline vs d-S+NE	1.500	0.562	No
Baseline vs ACh	9.500	3.557	Yes
Baseline vs NE	-0.833	-0.312	No
Baseline vs d-s	data	data	-
NE vs d-S+ACh	11.000	4.119	Yes
NE vs d-S+NE	2.333	0.874	No
NE vs d-S	-7.500	-2.808	No
NE vs ACh	10.333	3.869	Yes
ACh vs d-S+ACh	0.667	0.250	No
ACh vs d-S+NE	-8.000	-2.995	No
ACh vs d-S	-17.833	-6.677	Yes
d-S vs d-S+ACh	18.500	6.927	Yes
d-S vs d-S+NE	9.833	3.682	Yes
d-S+NE vs d-S+ACh	8.667	3.245	Yes

## Reversal of d-sotalol effects on the atrial ERP by NE and ACh

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d-S	-6- d-S+NE	-7- d-S+ACh
1	1.0000	90.0000	80.0000	62.0000	data	106.0000	80.0000
2	2.0000	102.0000	78.0000	64.0000	data	100.0000	84.0000
3	3.0000	118.0000	--	58.0000	data	102.0000	64.0000
4	4.0000	106.0000	86.0000	72.0000	data	100.0000	78.0000
5	5.0000	102.0000	88.0000	68.0000	data	84.0000	82.0000
6	7.0000	110.0000	100.0000	--	data	--	--
7							
8							
9Mean		104.6667	86.4000	64.8000	data	98.4000	77.6000
10SD		9.3524	8.6487	5.4037	data	8.4143	7.9246
11SEM		3.8181	3.8678	2.4166	data	3.7630	3.5440

10

15

20

25

30

**Reversal of d-sotalol effects on the atrial ERP by NE and ACh**

## One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.2769)  
 Equal Variance Test: Passed (P = 0.8519)

5	Group	N	Missing	
	Baseline	6	0	
	NE	6	1	
	ACh	6	1	
	d-S	6	0	
	d-S+NE	6	1	
	d-S+ACh	6	1	
10	Group	Mean	Std Dev	SEM
	Baseline	104.7	9.35	3.82
	NE	86.4	8.65	3.87
	ACh	64.8	5.40	2.42
	d-S	data	7.16	2.92
	d-S+NE	98.4	8.41	3.76
	d-S+ACh	77.6	7.92	3.54

Power of-performed test with alpha 0.0500: 1.0000

15	Source of Variance	DF	SS	MS
	Between Subjects	5	322.8	64.6
	Between Treatments	5	9269.7	1853.9
	Residual	21	1321.0	62.9
	Total	31	11735.5	378.6
15	Source of Variance	F	P	
	Between Subjects			
	Between Treatments	29.5	0.00000000813	

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.00000000813). To isolate the group or groups that differ from the others use a multiple comparison procedure.

20	Expected Mean Squares:	
	Approximate DF Residual	= 21.0
	E {MS(Subj)} = var(res)	+ 5.20 var(Subj)
	E {MS(Treatment)} var(res)	+ var(Treatment)

## All Pairwise Multiple Comparison Procedures (Bonferroni's method)

25	Comparison	Diff of Means	t	P<0.05
	Baseline vs d-S+ACh	25.68	5.27	Yes
	Baseline vs d-S+NE	4.88	1.00	No
	Baseline vs d-S	data	data	--
	Baseline vs ACh	38.48	7.89	Yes
	Baseline vs NE	18.17	3.75	Yes
	NE vs d-S+ACh	7.51	1.45	No
	NE vs d-S+NE	-13.29	-2.58	No
	NE vs d-S	-31.51	-6.50	Yes
	NE vs ACh	20.31	3.93	Yes
	ACh vs d-S+ACh	-12.80	-2.55	No
	ACh vs d-S+NE	-33.60	-6.70	Yes
	ACh vs d-S	-51.81	-10.63	Yes
	d-S vs d-S+ACh	39.01	8.00	Yes
	d-S vs d-S+NE	18.21	3.73	Yes
30	d-S+NE vs d-S+ACh	20.80	4.15	Yes

## Reversal of d-sotalol effects on the atrial EG by NE and Ach

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d-S	-6- d-S+NE	-7- d-S+ACh
1	1.0000	16.0000	38.0000	34.0000	data	16.0000	30.0000
2	2.0000	29.0000	46.0000	56.0000	data	26.0000	36.0000
3	3.0000	12.0000	--	72.0000	data	26.0000	62.0000
4	4.0000	28.0000	44.0000	42.0000	data	30.0000	44.0000
5	5.0000	34.0000	44.0000	34.0000	data	50.0000	36.0000
6	7.0000	36.0000	50.0000	--	data	--	--
7							
8							
9Mean		25.8333	44.4000	47.6000	data	29.6000	41.6000
10SD		9.7245	4.3359	16.3340	data	12.5220	12.4419
11SEM		3.9700	1.9391	7.3048	data	5.6000	5.5642

10

15

20

25

30

**Reversal of d-sotalol effects on the atrial EG by NE and ACh**

## One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.1727)  
 Equal Variance Test: Passed (P = 0.3543)

Group	N	Missing
Baseline	6	0
NE	6	1
ACh	6	1
d-S	6	0
d-S+NE	6	1
d-S+ACh	6	1

Group	Mean	Std Dev	SEM
Baseline	25.8	9.72	3.97
NE	44.4	4.34	1.94
ACh	47.6	16.33	7.30
d-S	data	8.80	3.59
d-S+NE	29.6	12.52	5.60
d-S+ACh	41.6	12.44	5.56

Power of performed test with alpha 0.0500: 0.9759

Source of Variance	DF	SS	MS
Between Subjects	5	1177.9	235.6
Between Treatments	5	3368.9	673.8
Residual	21	2071.3	98.6
Total	31	6283.9	202.7

Source of Variance	F	P
Between Subjects		
Between Treatments	6.83	0.000631

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.000631). To isolate the group or groups that differ from the others use a multiple comparison procedure.

## Expected Mean Squares:

Approximate DF Residual	= 21.0	
E{MS(Subj)} = var(res)	+ 5.20	var(Subj)
E{MS(Treatment)} var(res)	+	var(Treatment)
E{MS(Residual)} var(res)		

## All Pairwise Multiple Comparison Procedures (Bonferroni's method):

Comparison	Diff of Means	t	P<0.05
Baseline vs d-S+ACh	-17.87	-2.927	No
Baseline vs d-S+NE	-5.87	-0.962	No
Baseline vs d-S	data	data	--
Baseline vs ACh	-23.87	-3.855	Yes
Baseline vs NE	-19.23	-3.167	No
NE vs d-S+ACh	1.35	0.210	No
NE vs d-S+NE	13.35	2.066	No
NE vs d-S	22.56	3.716	Yes
NE vs ACh	-4.65	-0.719	No
ACh vs d-S+ACh	6.00	0.955	No
ACh vs d-S+NE	18.00	2.866	No
ACh vs d-S	27.21	4.456	Yes
d-S vs d-S+ACh	-21.21	-3.473	Yes
d-S vs d-S+NE	-9.21	-1.508	No
d-S+NE vs d-S+ACh	-12.00	-1.910	No

## Selective reversal of d,l-sotalol effects on the AF1CL by ACh

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d,l-S	-6- d,l-S+NE	-7- d,l-S+ACh
1	1.0000	118.0000	130.0000	112.0000	data	130.0000	124.0000
2	2.0000	124.0000	--	102.0000	data	145.0000	130.0000
3	3.0000	130.0000	121.0000	126.0000	data	144.0000	120.0000
4	4.0000	114.0000	--	100.0000	data	132.0000	116.0000
5	5.0000	150.0000	--	--	--	--	136.0000
6	6.0000	144.0000	140.0000	138.0000	data	154.0000	128.0000
7	7.0000	148.0000	136.0000	136.0000	data	158.0000	130.0000
8							
9Mean		132.5714	131.7500	119.0000	data	143.8333	126.2857
10SD		14.7745	8.2614	16.7212	data	11.2857	6.7753
11SEM		5.5842	4.1307	6.8264	data	4.6074	2.5608

10

15

20

25

30

**Selective reversal of d,l-sotalol effects on the AFICL by ACh**

## One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.6219)  
 Equal Variance Test: Passed (P = 0.1191)

5	Group	N	missing	
	Baseline	7	0	
	NE	7	3	
	ACh	7	1	
	d,l-S	7	1	
	d,l-S+NE	7	1	
10	d,l-S+ACh	7	0	
	Group	Mean	Std Dev	SEM
	Baseline	132.6	14.77	5.58
	NE	131.8	8.26	4.13
	ACh	119.0	16.72	6.83
	d,l-S	143.0	13.19	5.39
10	d,l-S+NE	143.8	11.29	4.61
	d,l-S+ACh	126.3	6.78	2.56

Power of performed test with alpha 0.0500: 1.0000

15	Source of Variance	DF	SS	MS
	Between Subjects	6	3715.4	619.2
	Between Treatments	5	3080.4	616.1
	Residual	24	979.3	40.8
	Total	35	7492.6	214.1

15	Source of Variance	F	P
	Between Subjects		
	Between Treatments	15.1	0.000000965

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.000000965). To isolate the group or groups that differ from the others use a multiple comparison procedure.

20	Expected Mean Squares:		
	Approximate DF Residual	= 24.0	
	E{MS(Subj)} = var(res)	+ 5.00	var(Subj)
	E{MS(Treatment)} = var(res)	+ var(Treatment)	

All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

25	Comparison	Diff of Means	t	P<0.05
	Baseline vs d,l-S+ACh	6.286	1.841	No
	Baseline vs d,l-S+NE	-13.524	-3.734	Yes
	Baseline vs d,l-S	data	data	--
	Baseline vs ACh	11.310	3.123	No
	Baseline vs NE	3.226	0.778	No
	NE vs d,l-S+ACh	3.060	0.738	No
	NE vs d,l-S+NE	-16.750	-3.983	Yes
	NE vs d,l-S	-15.917	-3.785	Yes
	NE vs ACh	8.083	1.922	No
	ACh vs d,l-S+ACh	-5.024	-1.387	No
	ACh vs d,l-S+NE	-24.833	-6.733	Yes
	ACh vs d,l-S	-24.000	-6.507	Yes
	d,l-S vs d,l-S+ACh	18.976	5.240	Yes
	d,l-S vs d,l-S+NE	-0.833	-0.226	No
30	d,l-S+NE vs d,l-S+ACh	19.810	5.470	Yes



## Selective reversal of d,1-sotalol effects on the atrial ERP b ACh

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d,l-S	-6- d,l-S+NE	-7- d,l-S+ACh
1	1.0000	86.0000	88.0000	58.0000	data	100.0000	74.0000
2	2.0000	100.0000	--	62.0000	data	122.0000	80.0000
3	3.0000	104.0000	86.0000	64.0000	data	114.0000	66.0000
4	4.0000	88.0000	--	64.0000	data	134.0000	88.0000
5	5.0000	120.0000	--	--	--	--	92.0000
6	6.0000	122.0000	102.0000	--	data	132.0000	108.0000
7	7.0000	114.0000	96.0000	70.0000	data	124.0000	80.0000
8							
9Mean		104.8571	93.0000	63.6000	data	121.0000	84.0000
10SD		14.5537	7.3937	4.3359	data	12.5698	13.6137
11SEM		5.5008	3.6968	1.9391	data	5.1316	5.1455

10

15

20

25

30

## Selective reversal of d,l-sotalol effects on the atrial ERP by ACh

## One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.0691)  
 Equal Variance Test: Passed (P = 0.8009)

5	Group	N	Missing	
	Baseline	7	0	
	NE	7	3	
	ACh	7	2	
	d,l-S	7	1	
	d,l-S+NE	7	1	
	d,l-S+ACh	7	0	
10	Group	Mean	Std Dev	SEM
	Baseline	104.9	14.55	5.50
	NE	93.0	7.39	3.70
	ACh	63.6	4.34	1.94
	d,l-S	data	19.21	7.84
	d,l-S+NE	121.0	12.57	5.13
	d,l-S+ACh	84.0	13.61	5.15

Power of performed test with alpha 0.0500: 1.0000

15	Source of Variance	DF	SS	MS
	Between Subjects	6	3472.2	578.7
	Between Treatments	5	13459.0	2691.8
	Residual	23	1785.8	77.6
	Total	34	19839.5	583.5
15	Source of Variance	F	P	
	Between Subjects			
	Between Treatments	34.7	0.000000000563	

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.000000000563). To isolate the group or groups that differ from the others use a multiple comparison procedure.

Expected Mean Squares:

Approximate DF Residual = 23.0

20	E{MS(Subj)} = var(res)	+ 4.83	var(Subj)
	E{MS(Treatment)} = var(res)	+ var(Treatment)	
	E{MS(Residual)} = var(res)		

All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

25	Comparison	Diff of Means	t	P<0.05
	Baseline vs d,l-S+ACh	20.86	4.428	Yes
	Baseline vs d,l-S+NE	-18.07	-3.617	Yes
	Baseline vs d,l-S	data	data	--
	Baseline vs ACh	35.70	6.738	Yes
	Baseline vs NE	10.55	1.844	No
	NE vs d,l-S+ACh	10.31	1.801	No
	NE vs d,l-S+NE	-28.62	-4.932	Yes
	NE vs d,l-S	-30.62	-5.277	Yes
	NE vs ACh	25.15	4.112	Yes
	ACh vs d,l-S+ACh	-14.85	-2.802	No
	ACh vs d,l-S+NE	-53.78	-9.986	Yes
	ACh vs d,l-S	-55.78	-10.357	Yes
	d,l-S vs d,l-S+ACh	40.93	8.193	Yes
	d,l-S vs d,l-S+NE	2.00	0.393	No
30	d,l-S+NE vs d,l-S+ACh	38.93	7.792	Yes

## Selective reversal of d,1-sotalol effects on the atrial EG by ACh

	-1- Dog#	-2- Baseline	-3- NE	-4- ACh	-5- d,l-S	-6- d,l-S+NE	-7- d,l-S+ACh
1	1.0000	32.0000	42.0000	54.0000	data	30.0000	50.0000
2	2.0000	24.0000	--	44.0000	data	23.0000	50.0000
3	3.0000	26.0000	35.0000	62.0000	data	30.0000	54.0000
4	4.0000	26.0000	--	26.0000	data	2.0000	28.0000
5	5.0000	30.0000	--	--	--	--	44.0000
6	6.0000	22.0000	38.0000	--	data	12.0000	20.0000
7	7.0000	30.0000	40.0000	66.0000	data	34.0000	50.0000
8							
9Mean		27.1429	38.7500	50.4000	data	21.8333	42.2857
10SD		3.6253	2.9861	16.0250	data	12.4325	13.0348
11SEM		1.3702	1.4930	7.1666	data	5.0755	4.9267

10

15

20

25

30

**Selective reversal of d,l-sotalol effects on the atrial EG by ACh**

## One Way Repeated Measures Analysis of Variance

Normality Test: Failed (P = 0.0328)  
 Equal Variance Test: Passed (P = 0.8347)

5	Group	N	Missing	
	Baseline	7	0	
	NE	7	3	
	ACh	7	2	
	d,l-S	7	1	
	d,l-S+NE	7	1	
	d,l-S+ACh	7	0	
10	Group	Mean	Std Dev	SEM
	Baseline	27.1	3.63	1.37
	NE	38.8	2.99	1.49
	ACh	50.4	16.02	7.17
	d,l-S	data	16.59	6.77
	d,l-S+NE	21.8	12.43	5.08
	d,l-S+ACh	42.3	13.03	4.93

Power of performed test with alpha 0.0500: 0.9996

15	Source of Variance	DF	SS	MS
	Between Subjects	6	2655.8	442.6
	Between Treatments	5	3733.0	746.6
	Residual	23	1645.3	71.5
	Total	34	8549.5	251.5
15	Source of Variance	F	P	
	Between Subjects			
	Between Treatments	10.4	0.0000253	

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.0000253). To isolate the group or groups that differ from the others use a multiple comparison procedure.

20	Expected Mean Squares:		
	Approximate DF Residual	= 23.0	
	E{MS(Subj)} = var(res)	+ 4.83	var(Subj)
	E{MS(Treatment)} = var(res)	+ var(Treatment)	

All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

25	Comparison	Diff of Means	t	P<0.05
	Baseline vs d,l-S+ACh	-15.14	-3.350	Yes
	Baseline vs d,l-S+NE	4.93	1.028	No
	Baseline vs d,l-S	data	data	--
	Baseline vs ACh	-21.89	-4.305	Yes
	Baseline vs NE	-8.32	-1.515	No
	NE vs d,l-S+ACh	-6.82	-1.242	No
	NE vs d,l-S+NE	13.25	2.379	No
	NE vs d,l-S	15.08	2.708	No
	NE vs ACh	-13.57	-2.312	No
	ACh vs d,l-S+ACh	6.75	1.328	No
	ACh vs d,l-S+NE	26.82	5.189	Yes
	ACh vs d,l-S	28.66	5.544	Yes
	d,l-S vs d,l-S+ACh	-21.90	-4.568	Yes
	d,l-S vs d,l-S+NE	-1.83	-0.375	No
30	d,l-S+NE vs d,l-S+ACh	-20.07	-4.186	Yes

## Effects of Autonomic Nervous Syst. on Atrial Fibrillation duration

	-1- Mean-10 AF	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+S)-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
5	1Dog #1	22.0000	9.0000	204.0000	9.0000	14.0000	260.0000	194.0000
	2Dog #2	33.0000	13.0000	189.0000	17.0000	13.0000	238.0000	190.0000
	3Dog #5	97.0000	44.0000	238.0000	31.0000	--	230.0000	209.0000
	4Dog #10	63.0000	56.0000	230.0000	36.0000	12.0000	214.0000	184.0000
	5Dog #12	22.0000	9.0000	190.0000	15.0000	--	182.0000	188.0000
	6Dog #13	34.0000	5.0000	189.0000	13.0000	--	208.0000	248.0000
	7Dog #14	13.0000	4.0000	218.0000	9.0000	--	183.0000	194.0000
	8							
10	9							
	10							
	11							
	12Mean	40.5714	20.0000	208.2857	18.5714	--	216.4286	201.0000
	13SD	29.5458	20.9921	20.5970	10.7060	--	28.6581	22.1736
	14SEM	11.1673	7.9343	7.7849	4.0465	--	10.8317	8.3808

15

20

25

30

**Effects of Autonomic Nervous Syst. on Atrial Fibrillation duration**

One Way Repeated Measures Analysis of Variance

Normality Test: Failed (P = 0.0192)

Test execution ended by user request, RM ANOVA on Ranks begun

Friedman Repeated Measures Analysis of Variance on Ranks

5	Group	N	Missing	
	Bas	7	0	
	V-D	7	0	
	V1-S1	7	0	
	(V+S)-D	7	0	
	V2-S1	7	0	
	V-S1+S-S10	7	0	
	Tested	7	0	
10	Group	Median	25%	75%
	Bas	33.00	22.00	55.8
	V-D	9.00	6.00	36.3
	V1-S1	204.00	189.25	227.0
	(V+S)-D	15.00	10.00	27.5
	V2-S1	214.00	189.25	236.0
	V-S1+S-S10	194.00	188.50	205.3
	Chi-square= 30.5 with 5 degrees of freedom. (P<0.0001)			

The differences in the median values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.0000116)

To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures.(Student-Newman-Keuls Method) :

15	Comparison	Diff of Ranks	p	q
	V1-S1 vs V-D	27.50	6	5.56
	V1-S1 vs (V+S)-D	25.50	5	6.10
	V1-S1 vs Bas	16.00	4	4.68
	V1-S1 vs V-S1+S-S10	4.00	3	1.51
	V1-S1 vs V2-S1	2.00	2	1.07
	V2-S1 vs V-D	25.50	5	6.10
	V2-S1 vs (V+S)-D	23.50	4	6.88
	V2-S1 vs Bas	14.00	3	5.29
	V2-S1 vs V-S1+S-S10	2.00	2	1.07
20	V-S1+S-S10 vs V-D	23.50	4	6.88
	V-S1+S-S10 vs (V+S)-D	21.50	3	8.13
	V-S1+S-S10 vs Bas	12.00	2	6.41
	Bas vs V-D	11.50	3	4.35
	Bas vs (V+S)-D	9.50	2	5.08
	(V+S)-D vs V-D	2.00	2	1.07
25	Comparison	P<0.05		
	V1-S1 vs V-D	Yes		
	V1-S1 vs (V+S)-D	Yes		
	V1-S1 vs Bas	Yes		
	V1-S1 vs V-S1+S-S10	No		
	V1-S1 vs V2-S1	Do Not Test		
	V2-S1 vs V-D	Yes		
	V2-S1 vs (V+S)-D	Yes		
	V2-S1 vs Bas	Yes		
	V2-S1 vs V-S1+S-S10	Do Not Test		
	V-S1+S-S10 vs V-D	Yes		
	V-S1+S-S10 vs (V+S)-D	Yes		
	V-S1+S-S10 vs Bas	Yes		
	Bas vs V-D	Yes		
30	Bas vs (V+S)-D	Yes		
	(V+S)-D vs V-D	No		

**Effects of Autonomic Nervous Syst. on AF duration (10 initiations)**

	-1- Dog#1/Init #	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+S)-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
5	1#1	3.0000	1.0000	204.0000	3.0000	20.0000	260.0000	194.0000
	2#2	2.0000	2.0000		2.0000	--		
	3#3	1.0000	2.0000		--	--		
	4#4	30.0000	4.0000		10.0000	--		
	5#5	45.0000	--		2.0000	14.0000		
	6#6	80.0000	5.0000		4.0000	--		
	7#7	12.0000	--		--	10.0000		
	8#8	14.0000	7.0000		14.0000	--		
	9#9	25.0000	46.0000		21.0000	10.0000		
	10#10	5.0000	2.0000		17.0000	--		
10	11							
	12Mean	21.7000	8.6250	204.0000	9.1250	13.5000	260.0000	194.0000
	13SD	24.9891	15.2310	0.0000	7.4917	4.7258	0.0000	0.0000
	14SEM	7.9023	5.3850	0.0000	2.6487	2.3629	0.0000	0.0000

## Effects of Autonomic Nervous Syst. on AF duration (10 initiations)

	-9-	-10-	-11-	-12-	-13-	-14-	-15-	-16-
Dog #2								
1#1		45.0000	10.0000	189.0000	--	12.0000	238.0000	190.0000
2#2		9.0000	2.0000		14.0000	24.0000		
3#3		14.0000	--		17.0000	20.0000		
4#4		75.0000	--		2.0000	10.0000		
5#5		2.0000	3.0000		4.0000	10.0000		
6#6		10.0000	14.0000		--	8.0000		
7#7		0.0000	21.0000		12.0000	5.0000		
8#8		17.0000	40.0000		22.0000	--		
9#9		5.0000	12.0000		10.0000	--		
10#10		154.0000	5.0000		53.0000	--		
11								
12Mean		33.1000	13.3750	189.0000	16.7500	12.7143	238.0000	190.0000
13SD		48.4251	12.4664	0.0000	16.0245	6.7999	0.0000	0.0000
14SEM		15.3134	4.4075	0.0000	5.6655	2.5701	0.0000	0.0000



## Effects of Autonomic Nervous Syst. on AF duration (10 initiations)

	-17-	-18-	-19-	-20-	-21-	-22-	-23-	-24-
Dog#5								
1#1	108.0000	80.0000	238.0000	--	--	--	230.0000	209.0000
2#2	36.0000	45.0000		24.0000	--	--		
3#3	42.0000	65.0000		104.0000	--	--		
4#4	80.0000	40.0000		23.0000	--	--		
5#5	30.0000	--		--	--	--		
6#6	104.0000	24.0000		5.0000	--	--		
7#7	174.0000	74.0000		--	--	--		
8#8	160.0000	12.0000		10.0000	--	--		
9#9	170.0000	--		17.0000	--	--		
10#10	69.0000	12.0000		33.0000				
11								
12Mean	97.3000	44.0000	238.0000	30.8571	--	--	230.0000	209.0000
13SD	55.4818	26.9974	0.0000	33.5630	--	--	0.0000	0.0000
14SEM	17.5449	9.5450	0.0000	12.6856	--	--	0.0000	0.0000

**Effects of Autonomic Nervous Syst. on AF duration (10 initiations)**

	-25-	-26-	-27-	-28-	-29-	-30-	-31-	-32-
Dog#10								
1#1	--	--	230.0000	4.0000	14.0000	214.0000	184.0000	
2#2	12.0000	--		7.0000	12.0000			
3#3	74.0000	18.0000		14.0000	--			
4#4	24.0000	100.0000		82.0000	--			
5#5	51.0000	--		90.0000	12.0000			
6#6	10.0000	45.0000		23.0000	--			
7#7	102.0000	--		21.0000	10.0000			
8#8	80.0000	60.0000		11.0000	--			
9#9	60.0000	44.0000		2.0000	--			
10#10	158.0000	69.0000		105.0000	--			
11								
12Mean	63.4444	56.0000	230.0000	35.9000	12.0000	214.0000	184.0000	
13SD	47.4845	27.6767	0.0000	39.8844	1.6330	0.0000	0.0000	
14SEM	15.8282	11.2990	0.0000	12.6126	0.8165	0.0000	0.0000	

## Effects of Autonomic Nervous Syst. on AF duration (10 initiations)

	-33-	-34-	-35-	-36-	-37-	-38-	-39-	-40-
Dog#12								
1#1		2.0000	1.0000	160.0000	11.0000	--	182.0000	188.0000
2#2		5.0000	20.0000	220.0000	13.0000			
3#3		36.0000	3.0000		--			
4#4		14.0000	8.0000		12.0000			
5#5		18.0000	7.0000		11.0000			
6#6		61.0000	5.0000		24.0000			
7#7		23.0000	12.0000		28.0000			
8#8		41.0000	23.0000		26.0000			
9#9		--	5.0000		2.0000			
10#10		2.0000	3.0000		5.0000			
11								
12Mean		22.4444	8.7000	190.0000	14.6667	--	182.0000	188.0000
13SD		20.1439	7.4394	42.4264	9.2466	--	0.0000	0.0000
14SEM		6.7146	2.3525	30.0000	3.0822	--	0.0000	0.0000

## Effects of Autonomic Nervous Syst. on AF duration (10 initiations)

	-41-	-42-	-43-	-44-	-45-	-46-	-47-	-48-
dog#13								
1#1		34.0000	1.0000	189.0000	5.0000	--	208.0000	248.0000
2#2		32.0000	2.0000		14.0000	22.0000		
3#3		54.0000	4.0000		24.0000	--		
4#4		87.0000	2.0000		32.0000	--		
5#5		60.0000	1.0000		11.0000	--		
6#6		2.0000	--		5.0000	--		
7#7		45.0000	--		8.0000	--		
8#8		4.0000	8.0000		12.0000	--		
9#9		7.0000	14.0000		2.0000	--		
10#10		11.0000	6.0000		14.0000			
11								
12Mean		33.6000	4.7500	189.0000	12.7000	22.0000	208.0000	248.0000
13SD		28.2654	4.4960	0.0000	9.2021	0.0000	0.0000	0.0000
14SEM		8.9383	1.5896	0.0000	2.9099	0.0000	0.0000	0.0000

## Effects of Autonomic Nervous Syst. on AF duration (10 initiations)

	-49-	-50-	-51-	-52-	-53-	-54-	-55-	-56-
Dog#14								
1#1		18.0000	2.0000	218.0000	14.0000	--	183.0000	194.0000
2#2		21.0000	4.0000		28.0000	--		
3#3		--	1.0000		2.0000	--		
4#4		--	2.0000		--	--		
5#5		18.0000	4.0000		--	--		
6#6		14.0000	3.0000		--	--		
7#7		--	2.0000		3.0000	--		
8#8		5.0000	5.0000		6.0000	--		
9#9		10.0000	15.0000		8.0000	--		
10#10		3.0000	2.0000		5.0000			
11								
12Mean		12.7143	4.0000	218.0000	9.4286	--	183.0000	194.0000
13SD		6.9213	4.0552	0.0000	9.0895	--	0.0000	0.0000
14SEM		2.6160	1.2824	0.0000	3.4355	--	0.0000	0.0000

## Effects of Autonomic Nervous System on atrial ERP duration

Effects of Autonomic Nervous System on Heart Rate									
		-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
	Dogs #	Bas	V-D	V1-S1	(V+S)-D	S-S10	V2-S1	V-S1+S-S10	
5	1	1.0000	104.0000	118.0000	94.0000	122.0000	102.0000	100.0000	92.0000
	2	2.0000	104.0000	108.0000	98.0000	112.0000	108.0000	102.0000	96.0000
	3	3.0000	85.0000	93.0000	73.0000	98.0000	88.0000	78.0000	75.0000
	4	4.0000	120.0000	125.0000	105.0000	120.0000	113.0000	105.0000	100.0000
	5	5.0000	124.0000	130.0000	118.0000	134.0000	120.0000	120.0000	108.0000
	6	6.0000	93.0000	117.0000	80.0000	130.0000	93.0000	83.0000	
	7	7.0000	88.0000	108.0000	78.0000	104.0000	94.0000	76.0000	76.0000
	8	8.0000	90.0000	100.0000	76.0000	106.0000	94.0000	78.0000	76.0000
	9	9.0000	84.0000	100.0000	76.0000	102.0000	96.0000	74.0000	76.0000
	10	10.0000	110.0000	115.0000	90.0000	110.0000	110.0000	90.0000	85.0000
	11	11.0000	98.0000	108.0000	86.0000	110.0000	102.0000	92.0000	82.0000
	12	12.0000	104.0000	112.0000	96.0000	116.0000	108.0000	90.0000	90.0000
	13	13.0000	76.0000	82.0000	66.0000	88.0000	82.0000	66.0000	70.0000
	14	14.0000	112.0000	120.0000	104.0000	124.0000	114.0000	102.0000	100.0000
10	15								
	16Mean		99.4286	109.7143	88.5714	112.5714	101.7143	89.7143	86.6154
	17SD		14.1895	12.8628	14.7007	12.7322	10.9715	14.8864	11.9620
	18SEM		3.7923	3.4377	3.9289	3.4028	2.9323	3.9786	3.3177

**Effects of Autonomic Nervous System on atrial ERP duration**

One Way Repeated Measures Analysis of Variance

Normality Test: Failed (P = 0.0181)

Equal Variance Test: Passed (P = 0.8712)

Group N Missing

Bas 14 0

V-D 14 0

V1-S1 14 0

(V+S)-D 14 0

S-S10 14 0

V2-S1 14 0

V-S1)+(S-S10 14 1

Group Mean Std Dev SEM

Bas 99.4 14.2 3.79

V-D 109.7 12.9 3.44

V1-S1 88.6 14.7 3.93

(V+S)-D 112.6 12.7 3.40

S-S10 101.7 11.0 2.93

V2-S1 89.7 14.9 3.98

V-S1)+(S-S10 86.6 12.0 3.32

Power of performed test with alpha 0.0500: 1.0000

Source of Variance DF SS MS

Between Subjects 13 14275.0 1098.1

Between Treatments 6 8987.0 1497.8

Residual 77 1572.9 20.4

Total 96 24834.0 258.7

Source of Variance F P

Between Subjects 73.3 8.49E-030

Between Treatments 73.3 8.49E-030

Residual

Total

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 8.49E-030). To isolate the group or groups that differ from the others use a multiple comparison procedure.

Expected Mean Squares:

Approximate DF Residual = 77.0

E{MS(Subj)} = var(res) + 6.92 var(Subj)

E{MS(Treatment)} = var(res) + var(Treatment)

E{MS(Residual)} = var(res)

All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

Comparison Dif f of Means t P&lt;0.05

Bas vs V-S1) + (S-S10 12.89 7.380 Yes

Bas vs V2-S1 9.71 5.687 Yes

Bas vs S-S10 -2.29 -1.338 No

Bas vs (V+S)-D -13.14 -7.694 Yes

Bas vs V1-S1 10.86 6.356 Yes

Bas vs V-D -10.29 -6.021 Yes

V-D vs V-S1) + (S-S10 23.17 13.270 Yes

V-D vs V2-S1 20.00 11.708 Yes

V-D vs S-S10 8.00 4.683 Yes

V-D vs (V+S)-D -2.86 -1.673 No

V-D vs V1-S1 21.14 12.377 Yes

V1-S1 vs V-S1)+(S-S10 2.03 1.162 No

V1-S1 vs V2-S1 -1.14 -0.669 No

V1-S1 vs S-S10 -13.14 -7.694 Yes

V1-S1 vs (V+S)-D -24.00 -14.049 Yes

(V+S)-D vs V-S1)+(S-S10 26.03 14.907 Yes

(V+S)-D vs V2-S1 22.86 13.380 Yes

(V+S)-D vs S-S10 10.86 6.356 Yes

S-S10 vs V-S1)+(S-S10 15.17 8.689 Yes

S-S10 vs V2-S1 12.00 7.025 Yes

V2-S1 vs V-S1)+(S-S10 3.17 1.817 No

## Effects of Autonomic Nervous System on atrial ERP dispersion

		-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
	Dogs #		Bas	V-D	V1-S1	(V+S)-D	S-S10	V2-S1	V-S1+S-S10
	1	1.0000	18.0000	11.0000	19.0000	8.0000	13.0000	20.0000	28.0000
	2	2.0000	21.0000	18.0000	24.0000	16.0000	16.0000	23.0000	21.0000
	3	3.0000	13.0000	10.0000	17.0000	13.0000	13.0000	15.0000	19.0000
	4	4.0000	18.0000	13.0000	21.0000	18.0000	15.0000	21.0000	16.0000
5	5	5.0000	21.0000	14.0000	16.0000	15.0000	20.0000	16.0000	16.0000
	6	6.0000	21.0000	15.0000	26.0000	17.0000	21.0000	21.0000	
	7	7.0000	15.0000	8.0000	16.0000	11.0000	15.0000	18.0000	13.0000
	8	8.0000	16.0000	10.0000	15.0000	9.0000	11.0000	11.0000	13.0000
	9	9.0000	11.0000	7.0000	18.0000	15.0000	9.0000	15.0000	19.0000
	10	10.0000	14.0000	7.0000	14.0000	14.0000	14.0000	14.0000	7.0000
	11	11.0000	18.0000	13.0000	18.0000	7.0000	8.0000	22.0000	23.0000
	12	12.0000	15.0000	11.0000	18.0000	17.0000	8.0000	16.0000	14.0000
	13	13.0000	11.0000	8.0000	17.0000	8.0000	8.0000	11.0000	10.0000
	14	14.0000	18.0000	12.0000	21.0000	9.0000	9.0000	18.0000	16.0000
10	15								
	16Mean		16.4286	11.2143	18.5714	12.6429	12.8571	17.2143	16.5385
	17SD		3.4354	3.2148	3.3904	3.8751	4.3120	3.8666	5.5620
	18SEM		0.9182	0.8592	0.9061	1.0357	1.1524	1.0334	1.5426



**Effects of Autonomic Nervous System on atrial ERP dispersion**

One Way Repeated Measures Analysis of Variance

Normality Test: Passed (P = 0.0589)

Equal Variance Test: Failed (P = 0.0181)

5	Group	N	Missing	
	Bas	14	0	
	V-D	14	0	
	V1-S1	14	0	
	(V+S)-D	14	0	
	S-S10	14	0	
	V2-S1	14	0	
	V-S1)+(S-S10	14	1	
10	Group	Mean Std Dev	Std Dev	SEM
	Bas	16.4	3.44	0.918
	V-D	11.2	3.21	0.859
	V1-S1	18.6	3.39	0.906
	(V+S)-D	12.6	3.88	1.036
	S-S10	12.9	4.31	1.152
	V2-S1	17.2	3.87	1.033
	V-S1) + (S-S10	16.5	5.56	1.543

Power of performed test with alpha 0.0500: 1.0000

15	Source of Variance	DF	SS	MS
	Between Subjects	13	735.2	56.55
	Between Treatments	6	666.3	111.05
	Residual	77	704.5	9.15
	Total	96	2088.7	21.76
	Source of Variance	F	P	
	Between Subjects			
	Between Treatments	12.1	0.00000000148	
	Residual			
	Total			

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 0.00000000148). To isolate the group or groups that differ from the others use a multiple comparison procedure.

20	Expected Mean Squares:		
	Approximate DF--Residual	= 77.0	
	E{MS(Subj)} = var(res)	+ 6.92	var(Subj)
	E{MS(Treatment)} = var(res)	+ var(Treatment)	
	E{MS(Residual)} = var(res)		

All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

25	Comparison	Diff of Means	t	P<0.05
	Bas vs V-S1)+(S-S10	-0.521	-0.446	No
	Bas vs V2-S1	-0.786	-0.687	No
	Bas vs S-S10	3.571	3.124	No
	Bas vs (V+S)-D	3.786	3.311	Yes
	Bas vs V1-S1	-2.143	-1.874	No
	Bas vs V-D	5.214	4.561	Yes
	V-D vs V-S1)+(S-S10	-5.735	-4.908	Yes
30	V-D vs V2-S1	-6.000	-5.248	Yes
	V-D vs S-S10	-1.643	-1.437	No
	V-D vs (V+S)-D	-1.429	-1.250	No
	V-D vs V1-S1	-7.357	-6.435	Yes
	V1-S1 vs V-S1)+(S-S10	1.622	1.388	No
	V1-S1 vs V2-S1	1.357	1.187	No
	V1-S1 vs S-S10	5.714	4.998	Yes
	V1-S1 vs (V+S)-D	5.929	5.186	Yes
	(V+S)-D vs V-S1)+(S-S10	-4.307	-3.685	Yes
	(V+S)-D vs V2-S1	-4.571	-3.998	Yes
	(V+S)-D vs S-S10	-0.214	-0.187	No
	S-S10 vs V-S1)+(S-S10	-4.092	-3.502	Yes
	S-S10 vs V2-S1	-4.357	-3.811	Yes
	V2-S1 vs V-S1)+(S-S10	0.265	0.226	No

**Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog1)**

	-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
		130.0000	130.0000	120.0000	130.0000	120.0000	120.0000	120.0000
	1RA-app	100.0000	120.0000	100.0000	130.0000	100.0000	120.0000	120.0000
	2LA-app	110.0000	120.0000	100.0000	120.0000	110.0000	100.0000	90.0000
	3RA-IVC	100.0000	120.0000	80.0000	110.0000	90.0000	80.0000	70.0000
	4RA-MVC	80.0000	100.0000	70.0000	120.0000	90.0000	80.0000	60.0000
5	5RA-SVC							
	6							
	7Mean	104.0000	118.0000	94.0000	122.0000	102.0000	100.0000	92.0000
	8SD	18.1659	10.9545	19.4936	8.3666	13.0384	20.0000	27.7489
	9SEM	8.1240	4.8990	8.7178	3.7417	5.8310	8.9443	12.4097

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog2)

-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
ERPdisp	Bas	V-D	V1-S1	(V+)S-D	S-S10	V2-S1	V-S1+S-S10
1RA-app	120.0000	120.0000	110.0000	120.0000	120.0000	110.0000	110.0000
2LA-app	130.0000	130.0000	130.0000	130.0000	120.0000	130.0000	120.0000
3RA-IVC	100.0000	110.0000	100.0000	120.0000	120.0000	110.0000	100.0000
4RA-MVC	80.0000	90.0000	70.0000	100.0000	90.0000	70.0000	70.0000
5R.A-SVC	90.0000	90.0000	80.0000	90.0000	90.0000	90.0000	80.0000
6							
7Mean	104.0000	108.0000	98.0000	112.0000	108.0000	102.0000	96.0000
8SD	210.7364	17.8885	23.8747	16.4317	16.4317	22.8035	20.7364
9SEM	9.2736	8.0000	10.6771	7.3485	7.3485	10.1980	9.2736

5

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (4 sites,dog3)

-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app	100.0000	100.0000	90.0000	110.0000	100.0000	90.0000	90.0000
2LA-app							
3RA-IVC	90.0000	100.0000	80.0000	100.0000	90.0000	90.0000	90.0000
4RA-MVC	80.0000	90.0000	70.0000	100.0000	90.0000	70.0000	70.0000
5RA-SVC	70.0000	80.0000	50.0000	80.0000	70.0000	60.0000	50.0000
6							
7Mean	85.0000	92.5000	72.5000	97.5000	87.5000	77.5000	75.0000
8SD	12.9099	9.5743	17.0783	12.5831	12.5831	15.0000	19.1485
9SEM	6.4550	4.7871	8.5391	6.2915	6.2915	7.5000	9.5743

5

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (4 sites,dog4)

-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
ERPdisp	Bas	V-D	V1-S1	(V+)S-D	S-S10	V2-S1	V-S1+S-S10
1RA-app	130.0000	130.0000	110.0000	130.0000	130.0000	110.0000	100.0000
2LA-app	140.0000	140.0000	130.0000	140.0000	120.0000	130.0000	120.0000
3RA-IVC	100.0000	110.0000	100.0000	100.0000	100.0000	100.0000	100.0000
4RA-MVC	110.0000	120.0000	80.0000	110.0000	100.0000	80.0000	80.0000
5RA-SVC							
6							
7Mean	120.0000	125.0000	105.0000	120.0000	112.5000	105.0000	100.0000
8SD	18.2574	12.9099	20.8167	18.2574	15.0000	20.8167	16.3299
9SEM	9.1287	6.4550	10.4083	9.1287	7.5000	10.4083	8.1650

5

10

15

20

25

30

**Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog5)**

	-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1	1RA-app	140.0000	140.0000	130.0000	150.0000	140.0000	130.0000	120.0000
2	2LA-app	150.0000	150.0000	140.0000	150.0000	140.0000	140.0000	130.0000
3	3RA-IVC	120.0000	120.0000	110.0000	130.0000	120.0000	110.0000	100.0000
4	4RA-MVC	100.0000	120.0000	110.0000	120.0000	100.0000	120.0000	100.0000
5	5RA-SVC	110.0000	120.0000	100.0000	120.0000	100.0000	100.0000	90.0000
6	7Mean	124.0000	130.0000	118.0000	134.0000	120.0000	120.0000	108.0000
7	8SD	20.7364	14.1421	16.4317	15.1658	20.0000	15.8114	16.4317
8	9SEM	9.2736	6.3246	7.3485	6.7823	8.9443	7.0711	7.3485

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (3 sites,dog6)

	-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app		110.0000	120.0000	100.0000	140.0000	110.0000	100.0000	
2LA-app		100.0000	130.0000	90.0000	140.0000	100.0000	90.0000	--
3RA-IVC		70.0000	100.0000	50.0000	110.0000	70.0000	60.0000	--
4RA-MVC								
5RA-SVC								
6								
7Mean		93.3333	116.6667	80.0000	130.0000	93.3333	83.3333	--
8SD		20.8167	15.2753	26.4575	17.3205	20.8167	20.8167	--
9SEM		12.0185	8.8192	15.2753	10.0000	12.0185	12.0185	--

5

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog7)

	-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
5	1RA-app	110.0000	120.0000	100.0000	120.0000	110.0000	100.0000	90.0000
	2LA-app	90.0000	110.0000	90.0000	100.0000	110.0000	90.0000	90.0000
	3RA-IVC	70.0000	100.0000	60.0000	110.0000	80.0000	60.0000	70.0000
	4RA-MVC	90.0000	110.0000	70.0000	100.0000	90.0000	70.0000	70.0000
	5RA-SVC	80.0000	100.0000	70.0000	90.0000	80.0000	60.0000	60.0000
6	7Mean	88.0000	108.0000	78.0000	104.0000	94.0000	76.0000	76.0000
	8SD	14.8324	8.3666	16.4317	11.4018	15.1658	18.1659	13.4164
	9SEM	6.6332	3.7417	7.3485	5.0990	6.7823	8.1240	6.0000

10

15

20

25

30



## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog8)

-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app	110.0000	110.0000	100.0000	110.0000	110.0000	90.0000	90.0000
2LA-app	90.0000	100.0000	80.0000	100.0000	100.0000	90.0000	90.0000
3RA-IVC	70.0000	90.0000	60.0000	100.0000	90.0000	70.0000	60.0000
4RA-MVC	80.0000	90.0000	70.0000	100.0000	90.0000	70.0000	70.0000
5RA-SVC	100.0000	110.0000	70.0000	120.0000	80.0000	70.0000	70.0000
6							
7Mean	90.0000	100.0000	76.0000	106.0000	94.0000	78.0000	76.0000
8SD	15.8114	10.0000	15.1658	8.9443	11.4018	10.9545	13.4164
9SEM	7.0711	4.4721	6.7823	4.0000	5.0990	4.8990	6.0000

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog9)

-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
ERPdisp	Bas	V-D	V1-S1	(V+)S-D	S-S10	V2-S1	V-S1+S-S10
1RA-app	90.0000	100.0000	90.0000	120.0000	100.0000	90.0000	90.0000
2LA-app	100.0000	100.0000	100.0000	100.0000	100.0000	90.0000	100.0000
3RA-IVC	80.0000	100.0000	70.0000	100.0000	100.0000	70.0000	70.0000
4RA-MVC	80.0000	110.0000	60.0000	110.0000	100.0000	60.0000	50.0000
5RA-SVC	70.0000	90.0000	60.0000	80.0000	80.0000	60.0000	70.0000
6							
7Mean	84.0000	100.0000	76.0000	102.0000	96.0000	74.0000	76.0000
8SD	11.4018	7.0711	18.1659	14.8324	8.9443	15.1658	19.4936
9SEM	5.0990	3.1623	8.1240	6.6332	4.0000	6.7823	8.7178

5

10

15

20

25

30

**Effective Refractory Period (ERP) dispersion (disp) (2 sites,dog10)**

-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app	100.0000	110.0000	80.0000	100.0000	100.0000	80.0000	80.0000
2LA-app	120.0000	120.0000	100.0000	120.0000	120.0000	100.0000	90.0000
3RA-IVC							
4RA-MVC							
5RA-SVC							
6							
7Mean	110.0000	115.0000	90.0000	110.0000	110.0000	90.0000	85.0000
8SD	14.1421	7.0711	14.1421	14.1421	14.1421	14.1421	7.0711
9SEM	10.0000	5.0000	10.0000	10.0000	10.0000	10.0000	5.0000

5

10

15

20

25

30

**Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog11)**

-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app	120.0000	120.0000	110.0000	110.0000	110.0000	110.0000	110.0000
2LA-app	110.0000	120.0000	100.0000	120.0000	110.0000	120.0000	100.0000
3RA-IVC	100.0000	110.0000	80.0000	110.0000	100.0000	80.0000	80.0000
4RA-MVC	80.0000	100.0000	70.0000	110.0000	100.0000	80.0000	60.0000
5RA-SVC	80.0000	90.0000	70.0000	100.0000	90.0000	70.0000	60.0000
6							
7Mean	98.0000	108.0000	86.0000	110.0000	102.0000	92.0000	82.0000
8SD	17.8885	13.0384	18.1659	7.0711	8.3666	21.6795	22.8035
9SEM	8.0000	5.8310	8.1240	3.1623	3.7417	9.6954	10.1980

5

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog12)

-1- ERPdisp	-2- Bas	-3- V-D	-4- V1-S1	-5- (V+)S-D	-6- S-S10	-7- V2-S1	-8- V-S1+S-S10
1RA-app	100.0000	100.0000	100.0000	100.0000	110.0000	90.0000	90.0000
2LA-app	130.0000	130.0000	120.0000	140.0000	120.0000	110.0000	110.0000
3RA-IVC	100.0000	110.0000	100.0000	120.0000	110.0000	100.0000	90.0000
4RA-MVC	100.0000	110.0000	90.0000	120.0000	100.0000	80.0000	90.0000
5RA-SVC	90.0000	110.0000	70.0000	100.0000	100.0000	70.0000	70.0000
6							
7Mean	104.0000	112.0000	96.0000	116.0000	108.0000	90.0000	90.0000
8SD	15.1658	10.9545	18.1659	16.7332	8.3666	15.8114	14.1421
9SEM	6.7823	4.8990	8.1240	7.4833	3.7417	7.0711	6.3246

5

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog13)

-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
ERPdisp	Bas	V-D	V1-S1	(V+)S-D	S-S10	V2-S1	V-S1+S-S10
1RA-app	80.0000	90.0000	80.0000	90.0000	90.0000	80.0000	80.0000
2LA-app	90.0000	90.0000	80.0000	100.0000	90.0000	70.0000	80.0000
3RA-IVC	80.0000	80.0000	70.0000	90.0000	80.0000	70.0000	70.0000
4RA-MVC	70.0000	80.0000	60.0000	80.0000	80.0000	60.0000	60.0000
5RA-SVC	60.0000	70.0000	40.0000	80.0000	70.0000	50.0000	60.0000
6							
7Mean	76.0000	82.0000	66.0000	88.0000	82.0000	66.0000	70.0000
8SD	11.4018	8.3666	16.7332	8.3666	8.3666	11.4018	10.0000
9SEM	5.0990	3.7417	7.4833	3.7417	3.7417	5.0990	4.4721

10

15

20

25

30

## Effective Refractory Period (ERP) dispersion (disp) (5 sites,dog14)

-1- ERPdisp	-2- Bas	-3- V-D	-4- VI-SI	-5- (V+)S-D	-6- S-S10	-7- V2-SI	-8- V-SI+S-S10
1RA-app	130.0000	130.0000	120.0000	130.0000	120.0000	120.0000	120.0000
2LA-app	130.0000	130.0000	130.0000	130.0000	120.0000	120.0000	110.0000
3RA-IVC	110.0000	120.0000	100.0000	130.0000	120.0000	100.0000	100.0000
4RA-MVC	100.0000	120.0000	90.0000	120.0000	110.0000	90.0000	90.0000
5RA-SVC	90.0000	100.0000	80.0000	110.0000	100.0000	80.0000	80.0000
6							
7Mean	112.0000	120.0000	104.0000	124.0000	114.0000	102.0000	100.0000
8SD	17.8885	12.2474	20.7364	8.9443	8.9443	17.8885	15.8114
9SEM	8.0000	5.4772	9.2736	4.0000	4.0000	8.0000	7.0711

10

15

20

25

30

## Effects of Autonomic Nervous System on Conduction Velocity

	Dogs #	-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
		Bas	V-D	V1-S1	(V+S)-D	S-S10	V2-S1	V-S1+S-S10	
5	1	2.0000	91.3000	87.3000	102.5000	90.0000	84.0000	100.0000	106.0000
	2	3.0000	100.0000	101.0000	100.0000	97.0000	100.0000	102.0000	108.0000
	3	4.0000	97.0000	90.0000	98.0000	87.0000	88.0000	108.0000	112.0000
	4	5.0000	96.5000	88.5000	107.0000	96.0000	104.0000	111.0000	117.0000
	5	6.0000	87.9000	80.0000	96.0000	82.0000	84.0000	91.0000	96.0000
	6	7.0000	70.5000	70.5000	87.0000	73.0000	78.0000	86.0000	93.0000
	7	8.0000	121.0000	102.0000	118.0000	94.0000	98.0000	125.0000	120.0000
	8	9.0000	96.4000	86.0000	104.0000	90.0000	94.0000	111.0000	116.0000
	9	11.0000	100.9000	88.0000	114.0000	84.0000	95.0000	112.0000	124.0000
	10	12.0000	88.5000	76.0000	98.0000	70.0000	77.0000	108.0000	114.0000
	11	13.0000	130.0000	110.0000	138.0000	104.0000	120.0000	148.0000	150.0000
	12	14.0000	117.0000	102.0000	128.0000	98.0000	115.0000	124.0000	128.0000
10	13								
	14								
	15								
	16Mean		99.7500	90.1083	107.5417	88.7500	94.7500	110.5000	115.3333
	17SD		16.2057	11.7344	14.5531	10.1813	13.6323	16.4510	15.0414
	18SEM		4.6782	3.3874	4.2011	2.9391	3.9353	4.7490	4.3421



**Effects of Autonomic Nervous System on Conduction Velocity**

## One Way Repeated Measures Analysis of Variance

Normality Test Passed (P = 0.6112)  
 Equal Variance Test: Passed (P = 0.3313)

5	Group	N	Missing	
	Bas	12	0	
	V-D	12	0	
	V1-S1	12	0	
	(V+S)-D	12	0	
	S-S10	12	0	
	V2-S1	12	0	
	V-S1+S-S10	12	0	
10	Group	Mean	Std Dev	SEM
	Bas	99.8	16.2	4.68
	V-D	90.1	11.7	3.39
	V1-S1	107.5	14.6	4.20
	(V+S)-D	88.8	10.2	2.94
	S-S10	94.8	13.6	3.94
	V2-S1	110.5	16.5	4.75
	V-S1+S-S10	115.3	15.0	4.34

Power of performed test with alpha 0.0500: 1.0000

15	Source of Variance	DF	SS	MS
	Between Subjects	11	13221.5	1202.0
	Between Treatments	6	7773.5	1295.6
	Residual	66	2162.0	32.8
	Total	83	23156.9	
	Source of Variance	F	P	
	Between Subjects			
	Between Treatments	39.6	5.14E-020	
	Residual			
	Total			

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = 5.14E-020). To isolate the group or groups that differ from the others use a multiple comparison procedure.

## All Pairwise Multiple Comparison Procedures (Bonferroni's method) :

20	Comparison	Diff of Means	t	P<0.05
	Bas vs V-S1+S-S10	-15.58	-6.669	Yes
	Bas vs V2-S1	-10.75	-4.601	Yes
	Bas vs S-S10	5.00	2.140	No
	Bas vs (V+S)-D	11.00	4.708	Yes
	Bas vs V1-S1	-7.79	-3.335	Yes
	Bas vs V-D	9.64	4.126	Yes
	V-D vs V-S1+S-S10	-25.22	-10.796	Yes
25	V-D vs V2-S1	-20.39	-8.727	Yes
	V-D vs S-S10	-4.64	-1.987	No
	V-D vs (V+S)-D	1.36	0.581	No
	V-D vs V1-S1	-17.43	-7.461	Yes
	V1-S1 vs V-S1+S-S10	-7.79	-3.335	Yes
	V1-S1 vs V2-S1	-2.96	-1.266	No
	V1-S1 vs S-S10	12.79	5.475	Yes
	V1-S1 vs (V+S)-D	18.79	8.042	Yes
30	(V+S)-D vs V-S1+S-S10	-26.58	-11.377	Yes
	(V+S)-D vs V2-S1	-21.75	-9.309	Yes
	(V+S)-D vs S-S10	-6.00	-2.568	No
	S-S10 vs V-S1+S-S10	-20.58	-8.809	Yes
	S-S10 vs V2-S1	-15.75	-6.741	Yes
	V2-S1 vs V-S1+S-S10	-4.83	-2.069	No

## Effects of Autonomic Nervous System on the Wavelength

	Dogs #	-1-	-2-	-3-	-4-	-5-	-6-	-7-	-8-
		Bas	V-D	V1-S1	(V+S)-D	S-S10	V2-S1	V-S1+S-S10	
5	1	2.0000	9.5000	9.4000	10.0000	10.0000	9.1000	10.0000	10.2000
	2	3.0000	8.5000	9.4000	7.3000	9.5000	8.8000	8.0000	8.1000
	3	4.0000	11.6000	11.3000	10.3000	10.4000	9.9000	11.3000	11.2000
	4	5.0000	12.0000	11.5000	12.6000	12.9000	12.5000	13.3000	12.6000
	5	6.0000	8.2000	9.4000	7.7000	10.7000	7.8000	7.6000	
	6	7.0000	6.2000	7.6000	6.8000	7.6000	7.3000	6.6000	7.7000
	7	8.0000	10.9000	10.2000	9.0000	10.0000	9.2000	9.8000	9.1000
	8	9.0000	8.1000	8.6000	7.9000	9.2000	9.0000	8.2000	8.8000
	9	11.0000	9.9000	9.5000	9.8000	9.2000	9.7000	10.3000	10.2000
	10	12.0000	9.2000	8.5000	9.4000	8.1000	8.3000	9.7000	10.3000
	11	13.0000	9.9000	9.0000	9.1000	9.2000	9.8000	9.8000	10.5000
	12	14.0000	13.1000	12.2000	13.3000	12.2000	13.1000	12.6000	12.8000
10	13								
	14								
	15								
	16Mean		9.7583	9.7167	9.4333	9.9167	9.5417	9.7667	10.1364
	17SD		1.9242	1.3537	1.9846	1.5183	1.7159	1.9888	1.6555
	18SEM		0.5555	0.3908	0.5729	0.4383	0.4954	0.5741	0.4991

15

20

25

30

**Effects of Autonomic Nervous System on the Wavelength**

One Way Repeated Measures Analysis of Variance

Normality Test: Passed

(P = 0.7307)

Equal Variance Test: Passed

(P = 0.7441)

5	Group N	N	Missing	
	Bas	12	0	
	V-D	12	0	
	V1-S1	12	0	
	(V+S)-D	12	0	
	S-S10	12	0	
	V2-S1	12	0	
	V-S1+S-S10	12	1	
10	Group	Mean	Std Dev	SEM
	Bas	9.76	1.92	0.555
	V-D	9.72	1.35	0.391
	V1-S1	9.43	1.98	0.573
	(V+S)-D	9.92	1.52	0.438
	S-S10	9.54	1.72	0.495
	V2-S1	9.77	1.99	0.574
	V-S1+S-S10	10.14	1.66	0.499

Power of performed test with alpha 0.0500: 0.0793

The power of the performed test (0.0793) is below the desired power of 0.8000. You should interpret the negative findings cautiously.

15	Source of Variance	DF	SS	MS
	Between Subjects	11	204.77	18.616
	Between Treatments	6	2.93	0.489
	Residual	65	28.10	0.432
	Total	82	236.59	2.885

20	Source of Variance	F	P
	Between Subjects		
	Between Treatments	1.13	0.355
	Residual		
	Total		

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.355).

Expected Mean Squares:

Approximate DF Residual = 65.0

 $E\{MS(\text{Subj})\} = \text{var}(\text{res}) + 6.91$  $\text{var}(\text{Subj})$  $E\{MS(\text{Treatment})\} = \text{var}(\text{res}) +$  $\text{var}(\text{Treatment})$  $E\{MS(\text{Residual})\} = \text{var}(\text{res})$

### CONCLUSION

Parasympathetic system nervous denervation significantly decreased the occurrence of atrial fibrillation. However, the activation of parasympathetic nervous system significantly increased the occurrence of atrial fibrillation and predominated the sympathetic nervous system activation effects. Local parasympathetic neurotransmitters infusion significantly increased the conversion of sustained atrial flutter to non sustained atrial fibrillation, and then to sinus rhythm. Furthermore, the local parasympathetic neurotransmitters infusion significantly reversed the effects of sotalol, a class 3 antiarrhythmic drug, on the reentry circuit characteristics during a sustained atrial flutter. This invention determined the significant effects of parasympathetic nervous system activation on the occurrence of atrial re-entrant arrhythmias. Furthermore, this invention illustrated the necessity of local ablation method of the atrial areas with the greatest density of parasympathetic innervation for the treatment of atrial arrhythmias, such as the areas near the sinoatrial nodal fat pad and septal.

**CLAIMS**

1. A method comprising the step of stimulating the parasympathetic nervous system via the right and left vagal nerves, wherein said method significantly increases the initiation of non sustained atrial fibrillation.

2. A method of On - Off voltage stimulation of the right and left vagal nerves comprising the step of significantly correlating said method with the On - Off-set of the atrial fibrillation episode.

3. A method comprising the step of deactivating the right and left vagal nerves, wherein said method significantly decreases the occurrence of atrial fibrillation.

4. A method comprising the step of stimulating the sympathetic nervous system via the right and left stellar ganglions, wherein said method significantly increases the initiation of non sustained atrial fibrillation.

5. A method comprising the step of stimulating the right and left vagal nerves in the presence of the right and left stellar ganglions, wherein stimulation is not significantly different compared to the method of stimulating the parasympathetic nervous system alone on the occurrence of atrial fibrillation.

6. A method comprising the step of locally infusing the parasympathetic neurotransmitter, wherein said method significantly increases the conversion of sustained atrial flutter to non sustained atrial fibrillation.

7. A method comprising the step of local infusing the parasympathetic neurotransmitter during a sustained atrial flutter, wherein said method significantly reverses the antiarrhythmic effects of a class 3 antiarrhythmic drug, sotalol.

8. The method, according to anyone of claims 1, 2 and 3, wherein locally infusing the parasympathetic nervous system blocker significantly prevents the occurrence of atrial fibrillation.

5 9. The method, according to anyone of claims 1, 2 and 6, wherein activating the parasympathetic tone significantly converts a sustained atrial flutter to sinus rhythm.

10 10. The method, according to anyone of claims 1, 2, 3 and 6, wherein inhibiting the parasympathetic tone significantly converts a sustained atrial fibrillation to sinus rhythm.

15 11. The method, according to anyone of claims 6 and 7, wherein infusing the parasympathetic nervous system blocker significantly preserves the antiarrhythmic effects of class 3 antiarrhythmic drugs on the occurrence of a sustained atrial re-entrant arrhythmias.

20 12. The method, according to anyone of claims 6 and 7, wherein infusing the parasympathetic nervous system blocker significantly preserves the antiarrhythmic effects of class I, II, IV, V or any other drugs used for the treatment of the atrial re-entrant arrhythmias.

25 13. The method, according to anyone of claims 1, 2, 3 and 6, wherein catheter ablation of the atrial areas with the greatest density of parasympathetic fibers innervation significantly converts and prevents the occurrence of the atrial re-entrant arrhythmias.

30

**ABSTRACT OF THE DISCLOSURE**

Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransmitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters / blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.

**UTILITY DECLARATION  
AND POWER OF ATTORNEY  
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **THE USE OF AUTONOMIC NERVOUS SYSTEM EUROTRANSMITTERS INHIBITION AND ATRIAL PARASYMPATHETIC FIBERS ABLATION FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS AND TO PRESERVE DRUG EFFECTS**, the specification of which

(Check One)

☒  
☐

is attached hereto OR

was filed on \_\_\_\_\_ as United States Application Serial No. \_\_\_\_\_ or PCT International Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned




POWER OF ATTORNEY: As a named inventor, I hereby appoint as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the United States Patent and Trademark Office, and in countries other than the United States, and to do all things necessary or appropriate therefor before any competent International Authorities in connection with any international patent application(s) corresponding to the above-identified invention application, all of the registered practitioners identified by Customer Number 22249:



LYON & LYON LLP  
Suite 4700  
633 W. Fifth Street  
Los Angeles, CA 90071  
(213) 489-1600

Please send all correspondence to the attention of Charles S. Berkman, and direct all telephone calls to (858) 552-8400.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name MARC	MIDDLE Initial MOUNIR	LAST Name RAHME	
	RESIDENCE & CITIZENSHIP	City SAN DIEGO	State or Foreign Country CALIFORNIA	Country of Citizenship CANADA	
	POST OFFICE ADDRESS	5128 BOWDEN AVENUE	City SAN DIEGO	State or Country CALIFORNIA	Zip Code 92117
INVENTOR'S SIGNATURE  DATE 5/6-2000					